High-yield algorithms, recognition patterns, and exam traps — built for rapid last-minute recall.
This document covers 23 core Gynecology topics for the exam. Each chapter follows the MedCORE format with its own accent color. Content is designed for rapid revision and discrimination between high-yield diagnoses.
| Parameter | Value / Threshold |
|---|---|
| Normal menstrual cycle length | 21-35 days |
| HMB blood loss | >80 mL per cycle |
| Postmenopausal bleeding definition | Bleeding >12 months amenorrhea |
| Primary amenorrhea (no menses by age) | 15 (or 13 if no secondary sexual characteristics) |
| Secondary amenorrhea | Absent menses >3 months |
| Menopause diagnosis (clinical) | Amenorrhea × 12 months + symptoms >45 yr |
| FSH in menopause | >25-30 IU/L |
| Endometrial stripe threshold (PMB) | <5 mm → <1% cancer risk; ≥5 mm → biopsy |
| Oligo/anovulation | <9 periods/year OR cycles >35 days |
| PCO on ultrasound | ≥12 follicles (2-9 mm) OR volume >10 mL |
| Copper IUD duration | 10-12 years |
| LNG-IUS (Mirena) duration | 5-7 years |
| Copper IUD — EC efficacy | >99% (most effective EC) |
| BRCA1 ovarian cancer risk | 40-50% lifetime |
| BRCA2 ovarian cancer risk | 20-30% lifetime |
| Semen analysis normal count | ≥16 million/mL (total ≥39 million) |
| Post-void residual normal | <50-100 mL |
| Parameter | Value / Threshold |
|---|---|
| Vaginal pH normal | 3.8-4.5 |
| Pap screening start | Age 21 |
| Pap screening stop | Age 65 (adequate prior screening) |
| Cervical cancer peak incidence | 45-55 years |
| Endometrial cancer peak incidence | 60-70 years |
| Ovarian cancer peak incidence | 60-70 years |
| Ovarian torsion highest risk size | 5-10 cm masses |
| IUD emergency contraception window | Insert within 5 days |
| Normal vaginal pH | 3.8-4.5 |
| Vaginal pH in BV/trichomoniasis | >4.5 |
| Progesterone confirming ovulation | ≥10 ng/mL (day 21 of 28-day cycle) |
| Cervical cancer 5-year survival (stage IA) | 95% |
| Ovarian cancer 5-year survival (stage IV) | 15-20% |
Most common cause of AUB — AUB-O (ovulatory dysfunction)
Most common cause of primary amenorrhea — Constitutional delay
Most common benign breast tumor — Fibroadenoma
Most common STI — HPV (genital warts)
Most common cause of PID — Chlamydia trachomatis
Most common cervical cancer symptom — Postcoital bleeding
Most common endometrial cancer symptom — Postmenopausal bleeding
Most lethal gynecologic malignancy — Ovarian cancer
Gold standard for endometriosis diagnosis — Laparoscopy with biopsy
Gold standard for endometrial cancer diagnosis — Endometrial biopsy
Gold standard for intrauterine pathology — Hysteroscopy
Gold standard for cervical cancer local staging — MRI pelvis
First-line PCOS treatment (all) — Lifestyle modification (5-10% weight loss)
First-line ovulation induction PCOS — Letrozole
First-line stress incontinence — Kegel exercises
Most effective reversible contraception — LARC (IUD or implant)
Most effective emergency contraception — Copper IUD (>99%)
Most effective treatment for hot flashes — HRT
Most important ovarian cancer prognostic factor — Optimal debulking (no visible residual)
Most common ovarian mass in reproductive age — Functional cyst
A 28-year-old woman presents with heavy menstrual bleeding for 1 year — changing pads every 1-2 hours, passing clots >2.5 cm, and feeling fatigued. Bleeding lasts 8-9 days per cycle. She is not on any contraception. Her BMI is 32. Pelvic exam reveals a mildly enlarged irregular uterus.
Recognition Pattern — HMB (blood loss >80 mL/cycle, changing pads every 1-2 hours, clots >2.5 cm, bleeding >7 days) + anemia symptoms (fatigue, pallor, palpitations) + possible structural (irregular uterus) + ovulatory (obesity) causes.
Reproductive-age woman with prolonged heavy bleeding — use PALM-COEIN classification; always rule out pregnancy first, then assess for structural (PALM) vs functional (COEIN) causes.
PALM-COEIN — Polyp, Adenomyosis, Leiomyoma, Malignancy — Coagulopathy, Ovulatory, Endometrial, Iatrogenic, Not classified (exam, FCPS)
Menorrhagia (HMB) — Blood loss >80 mL/cycle OR pads every 1-2 hours (Clinical definition)
Metrorrhagia — Bleeding between regular periods — think cervical pathology, endometrial polyp, malignancy (exam)
Postmenopausal bleeding — Bleeding >12 months after amenorrhea = cancer until proven otherwise (exam, USMLE)
β-hCG first always — Never forget pregnancy test in any reproductive-age woman with AUB — ectopic, miscarriage, molar pregnancy can all present as AUB.
Endometrial biopsy threshold — ≥45 years OR any age with risk factors (obesity, PCOS, Lynch, unopposed estrogen) needs endometrial biopsy — don't rely on ultrasound alone.
HMB since menarche — HMB that started at menarche suggests coagulopathy — von Willebrand disease is most common inherited bleeding disorder in women.
TSH in AUB — Hypothyroidism causes ovulatory dysfunction → HMB. Always check TSH in AUB workup.
How it's tested Age + bleeding pattern + menstrual history → classify using PALM-COEIN. Key branch: structural (PALM) needs imaging/surgery vs functional (COEIN) needs medical management.
The disguise Young woman with HMB and irregular uterus — distractors suggest fibroids but the real diagnosis is AUB-O from anovulation (PCOS). The discriminator is age and associated features (acanthosis nigricans, obesity).
Discrimination rewarded Pregnancy test is the FIRST step, not ultrasound. Endometrial biopsy threshold is age ≥45 (not young age). Tranexamic acid is first-line medical, not OCPs (OCPs are for cycle regulation, not acute bleeding reduction).
Most common cause of AUB — AUB-O (ovulatory dysfunction) — extremes of reproductive age
Gold standard for intrauterine pathology — Hysteroscopy
Best imaging for submucosal fibroid — Hysteroscopy or saline infusion sonography (SIS)
AUB-O timing — Adolescence and perimenopause (extremes of reproductive age)
| E |
|---|
| β-hCG first always — Never forget pregnancy test in any reproductive-age woman with AUB — ectopic, miscarriage, molar pregnancy can all present as AUB. |
| W |
|---|
| Why it matters — Pregnancy test is the FIRST step, not ultrasound. Endometrial biopsy threshold is age ≥45 (not young age). Tranexamic acid is first-line medical, not OCPs (OCPs are for cycle regulation, not acute bleeding reduction). |
| P |
|---|
| Pearl — Most common cause of AUB: AUB-O (ovulatory dysfunction) — extremes of reproductive age |
A 17-year-old girl presents with no menstrual periods ever. She has normal breast development (Tanner 4) but sparse pubic hair. On ultrasound, no uterus is visualized. Karyotype returns 46,XY.
Recognition Pattern — Primary amenorrhea (no menses by age 15 with normal secondary sexual characteristics, or by age 13 if no secondary sexual characteristics) + normal breast development (androgen-sensitive) + absent uterus + 46,XY = androgen insensitivity syndrome (CAIS).
Primary amenorrhea + normal breast development + absent uterus → 46,XY = CAIS; if 46,XX = MRKH syndrome. Primary amenorrhea + no breast development + short stature + webbed neck → Turner syndrome (45,XO).
Primary amenorrhea — No menses by age 15 (or 13 if no secondary sexual characteristics) (exam, USMLE)
Secondary amenorrhea — Absent menses >3 months in previously cycling woman (exam)
CAIS (Complete Androgen Insensitivity) — 46,XY, female phenotype, blind vagina, no uterus, testes, normal breasts (exam, FCPS)
MRKH syndrome — Müllerian agenesis — absent uterus/upper vagina, normal ovaries, 46,XX (exam)
Sheehan syndrome — Postpartum pituitary necrosis after massive PPH → failure to lactate, amenorrhea (exam)
Asherman syndrome — Intrauterine adhesions after D&C → amenorrhea + cyclic pain (exam)
Functional hypothalamic amenorrhea — Low energy availability + menstrual dysfunction + low BMD (athlete triad) (exam)
Karyotype in absent uterus — No uterus on US in primary amenorrhea → karyotype is essential. 46,XY = CAIS (testes present → normal breasts from androgen insensitivity). 46,XX = MRKH (normal ovaries, can have IVF via surrogate).
FSH before estrogen — Don't start HRT before checking FSH in primary amenorrhea — you'll suppress it and lose diagnostic information.
Constitutional delay first — Most common cause of primary amenorrhea is constitutional delay — not Turner, not CAIS. Family history of late menarche is key.
Sheehan after PPH — Secondary amenorrhea + failure to lactate after massive postpartum hemorrhage = Sheehan syndrome (pituitary necrosis). Can also cause hypothyroidism, adrenal insufficiency.
Most common cause of primary amenorrhea — Constitutional delay
Primary amenorrhea + normal breasts + no uterus — Karyotype: 46,XY = CAIS; 46,XX = MRKH
Secondary amenorrhea + galactorrhea — Hyperprolactinemia (check prolactin, MRI pituitary)
Amenorrhea after D&C — Asherman syndrome (hysteroscopic adhesiolysis)
Amenorrhea in athlete — Functional hypothalamic amenorrhea (FHA)
| E |
|---|
| Karyotype in absent uterus — No uterus on US in primary amenorrhea → karyotype is essential. 46,XY = CAIS (testes present → normal breasts from androgen insensitivity). 46,XX = MRKH (normal ovaries, can have IVF via surrogate). |
| W |
|---|
| FSH before estrogen — Don't start HRT before checking FSH in primary amenorrhea — you'll suppress it and lose diagnostic information. |
| P |
|---|
| Pearl — Most common cause of primary amenorrhea: Constitutional delay |
A 19-year-old college student presents with severe cramping lower abdominal pain that starts on the first day of her period and lasts 48-72 hours. She also reports nausea and headache during episodes. She has regular cycles. Her pelvic exam is normal. Symptoms improve significantly with ibuprofen.
Recognition Pattern — Adolescent/young adult + cramping pain starting with menses + regular cycles + normal pelvic exam + excellent response to NSAIDs = classic primary dysmenorrhea (excess prostaglandin F2α → uterine hypercontractility + ischemia).
Cramping pain starting with menstrual flow in a young woman with normal exam and excellent NSAID response = primary dysmenorrhea. Pain starting BEFORE menses or persisting after flow stops = secondary dysmenorrhea.
| Primary Dysmenorrhea | Secondary Dysmenorrhea | |
|---|---|---|
| Onset | Within 6-12 months of menarche | Years after menarche |
| Age | Adolescents, <20 years | >25 years |
| Pain timing | Just before / first 48-72 hrs of flow | Before menses, throughout cycle |
| Pain duration | 48-72 hours | Longer, may persist |
| Pain quality | Cramping, suprapubic, radiates | Dull, aching, varies by cause |
| Pelvic exam | Normal | Abnormal findings |
| NSAID response | Excellent | Poor |
| Cause | Prostaglandin excess | Endometriosis, adenomyosis, fibroids, PID |
NSAID timing — NSAIDs are most effective when started 1-2 days before expected menses — prevent prostaglandin buildup, don't just treat it.
Primary = prostaglandin — Primary dysmenorrhea is caused by excess prostaglandin F2α released when endometrium breaks down — this is why pain starts WITH menstrual flow, not before.
Nulliparous + boggy uterus — 32-year-old nulliparous with progressive dysmenorrhea + heavy bleeding + boggy enlarged uterus = adenomyosis (endometrial glands IN myometrium), NOT endometriosis.
Primary dysmenorrhea mechanism — Excess prostaglandin F2α → uterine hypercontractility, ischemia, pain
Best initial treatment — NSAIDs (ibuprofen/mefenamic acid) started 1-2 days before menses
Progressive dysmenorrhea + dyspareunia + infertility — Endometriosis
Dysmenorrhea + heavy bleeding + boggy uterus — Adenomyosis
| E |
|---|
| NSAID timing — NSAIDs are most effective when started 1-2 days before expected menses — prevent prostaglandin buildup, don't just treat it. |
| W |
|---|
| Primary = prostaglandin — Primary dysmenorrhea is caused by excess prostaglandin F2α released when endometrium breaks down — this is why pain starts WITH menstrual flow, not before. |
| P |
|---|
| Pearl — Primary dysmenorrhea mechanism: Excess prostaglandin F2α → uterine hypercontractility, ischemia, pain |
A 24-year-old woman with BMI 33 presents with irregular periods (6-7 per year) and difficulty conceiving for 1 year. She has acne on her face and chest, and notices excess hair growth on her chin and lower abdomen. On exam, acanthosis nigricans is noted on her neck and axillae.
Recognition Pattern — Oligomenorrhea (<9 periods/year) + clinical hyperandrogenism (acne, hirsutism) + obesity + acanthosis nigricans (insulin resistance) + infertility (anovulation) = classic PCOS. Need 2/3 Rotterdam criteria for diagnosis.
Oligomenorrhea + hirsutism/acne + obesity + acanthosis nigricans + infertility = PCOS until proven otherwise. Remember: polycystic ovaries on US alone ≠ PCOS (need 2/3 Rotterdam criteria).
PCOS (Rotterdam criteria) — 2 of 3: oligo/anovulation + hyperandrogenism + PCO morphology (exam, USMLE)
Stein-Leventhal syndrome — Original name for PCOS (Historical)
Acanthosis nigricans — Velvety hyperpigmentation — marker of insulin resistance (Clinical sign)
LH:FSH ratio >2:1 — Classic but NOT diagnostic of PCOS (exam)
Oligo/anovulation — <9 periods/year OR cycles >35 days (Criteria)
PCO morphology — ≥12 follicles (2-9 mm) per ovary OR ovarian volume >10 mL (Ultrasound)
PCO on US ≠ PCOS — Polycystic ovarian morphology is found in 20-30% of normal women. Need 2/3 Rotterdam criteria (oligo/anovulation + hyperandrogenism + PCO) for diagnosis.
First-line treatment — Lifestyle modification (weight loss) is first-line for ALL PCOS patients — not OCPs, not metformin. Weight loss of 5-10% restores ovulation in many.
Letrozole over clomiphene — Letrozole is superior to clomiphene for ovulation induction in PCOS — higher live birth rates, lower multiple pregnancy risk.
Rapid virilization — Very high testosterone + rapid onset of virilization (deep voice, clitoromegaly, balding) = androgen-secreting tumor, NOT PCOS. Image adrenals and ovaries.
Rotterdam criteria (2 of 3) — Oligo/anovulation + hyperandrogenism + PCO morphology
First-line treatment all PCOS — Lifestyle modification — 5-10% weight loss
First-line ovulation induction — Letrozole (superior to clomiphene)
Why regular bleeds important — Prevent endometrial hyperplasia from unopposed estrogen
Why LH:FSH ratio elevated — Increased GnRH pulsatility → preferential LH secretion
| E |
|---|
| PCO on US ≠ PCOS — Polycystic ovarian morphology is found in 20-30% of normal women. Need 2/3 Rotterdam criteria (oligo/anovulation + hyperandrogenism + PCO) for diagnosis. |
| W |
|---|
| First-line treatment — Lifestyle modification (weight loss) is first-line for ALL PCOS patients — not OCPs, not metformin. Weight loss of 5-10% restores ovulation in many. |
| P |
|---|
| Pearl — Rotterdam criteria (2 of 3): Oligo/anovulation + hyperandrogenism + PCO morphology |
A 29-year-old woman presents with amenorrhea for 6 months and milky discharge from both breasts. She is not pregnant and not breastfeeding. She has no headache or visual changes. Her medications include metoclopramide for gastritis. Serum prolactin is 180 ng/mL. TSH is normal.
Recognition Pattern — Secondary amenorrhea + galactorrhea + elevated prolactin + normal TSH + medication (metoclopramide) — prolactin >200 ng/mL suggests prolactinoma; 100-200 with offending drug suggests drug-induced; rule out hypothyroidism (high TRH stimulates prolactin).
Amenorrhea + galactorrhea = check prolactin. Medications (antipsychotics, metoclopramide) are most common cause. If prolactin >200 and no drugs — prolactinoma until proven otherwise.
Drug-induced first — Most common cause of hyperprolactinemia is medications, not prolactinoma. Antipsychotics, metoclopramide are classic. Always check meds before MRI.
TSH before MRI — Primary hypothyroidism causes elevated TRH → stimulates prolactin. Treat the thyroid first before doing MRI for prolactinoma.
Cabergoline > bromocriptine — Cabergoline is preferred — dosed twice weekly (vs BD/TDS), better tolerated, more effective at shrinking tumors.
Pregnancy and prolactinoma — Stop dopamine agonists once pregnancy confirmed (unless macroadenoma with visual concerns). Microprolactinomas have low risk of growth in pregnancy.
Most common pituitary tumor — Prolactinoma
First-line treatment for prolactinoma — Dopamine agonist (cabergoline preferred)
Hyperprolactinemia + high TSH — Primary hypothyroidism (TRH stimulates prolactin)
Why prolactin causes amenorrhea — Inhibits GnRH → ↓ LH/FSH → hypogonadism
| E |
|---|
| Drug-induced first — Most common cause of hyperprolactinemia is medications, not prolactinoma. Antipsychotics, metoclopramide are classic. Always check meds before MRI. |
| W |
|---|
| TSH before MRI — Primary hypothyroidism causes elevated TRH → stimulates prolactin. Treat the thyroid first before doing MRI for prolactinoma. |
| P |
|---|
| Pearl — Most common pituitary tumor: Prolactinoma |
A 34-year-old woman and her 36-year-old partner present with inability to conceive after 18 months of regular unprotected intercourse. She has regular 28-day cycles. He has no known medical problems. She has no prior surgeries. His semen analysis shows oligospermia (8 million/mL).
Recognition Pattern — Primary infertility (no prior conception) + regular cycles (likely ovulatory) + male factor (oligospermia) — need full couple workup. Start with semen analysis (easiest, non-invasive), then assess ovulation, tubal patency, and uterine cavity.
Inability to conceive after 1 year (<35 years) or 6 months (>35 years). Start workup with semen analysis (most accessible), then assess ovulation (day 21 progesterone), tubal patency (HSG), and uterine cavity.
Primary infertility — No prior conception after 1 year of unprotected intercourse (Definition)
Secondary infertility — Prior conception but now unable to conceive (Definition)
Oligospermia — Sperm count <16 million/mL (exam)
Asthenospermia — Motility <42% (exam)
Azoospermia — No sperm in ejaculate (exam)
Ovarian reserve — FSH day 3, AMH, antral follicle count — assess egg quantity (exam)
Semen analysis first — Semen analysis is the easiest, cheapest, and least invasive test in the infertility workup — do it FIRST.
Hydrosalpinx before IVF — Hydrosalpinx fluid is embryotoxic — consider salpingectomy before IVF to improve success rates.
Day 21 progesterone — Measures ovulation, NOT pregnancy. Progesterone ≥10 ng/mL confirms ovulation occurred. If cycles irregular, time it 7 days before expected menses.
Age >35 — expedite — Women >35 years: start workup after 6 months (not 12). Ovarian reserve testing (AMH, FSH, AFC) is important. Don't delay treatment.
First test in infertility workup — Semen analysis (easy, non-invasive)
Gold standard for tubal patency — Hysterosalpingography (HSG)
Most common correctable male infertility — Varicocele
What day 21 progesterone assesses — Ovulation (not pregnancy)
| E |
|---|
| Semen analysis first — Semen analysis is the easiest, cheapest, and least invasive test in the infertility workup — do it FIRST. |
| W |
|---|
| Hydrosalpinx before IVF — Hydrosalpinx fluid is embryotoxic — consider salpingectomy before IVF to improve success rates. |
| P |
|---|
| Pearl — First test in infertility workup: Semen analysis (easy, non-invasive) |
A 22-year-old sexually active woman presents with purulent vaginal discharge and dysuria for 3 days. She has a new partner and used condoms inconsistently. On exam, there is mucopurulent cervical discharge and cervical motion tenderness. Temperature is 38.1°C.
Recognition Pattern — Young sexually active woman + mucopurulent cervicitis + dysuria + fever + cervical motion tenderness = consider chlamydia/gonorrhea coinfection with possible PID. Always test for both and treat empirically.
Mucopurulent cervicitis + dysuria in sexually active young woman = chlamydia/gonorrhea until proven otherwise. If cervical motion tenderness + fever = PID. Treat empirically before results return.
| Chlamydia | Gonorrhea | Syphilis | HSV | HPV | |
|---|---|---|---|---|---|
| Pathogen | C. trachomatis | N. gonorrhoeae | T. pallidum | HSV-1/HSV-2 | HPV (6,11,16,18, etc.) |
| Presentation | 70-80% asymptomatic; mucopurulent cervicitis | 50% asymptomatic; purulent discharge | Painless chancre (primary) → rash (secondary) | Painful grouped vesicles on erythematous base | Flesh-colored cauliflower-like lesions |
| Diagnosis | NAAT (swab/urine) — gold standard | NAAT (swab/urine); Culture if resistance | VDRL/RPR (screen); FTA-ABS/TPPA (confirm) | PCR; viral culture; type-specific IgG | Clinical diagnosis; biopsy if uncertain |
| Treatment | Doxycycline 100mg BD × 7d | Ceftriaxone 500mg IM + doxy | Benzathine penicillin G 2.4 million U IM | Acyclovir/Valacyclovir | Cryotherapy; Imiquimod; Podofilox |
| Complication | PID → infertility, ectopic | DGI (tenosynovitis + dermatitis + arthritis) | Neurosyphilis, aortitis, gummas | Neonatal herpes (C-section if active) | Cervical cancer (types 16, 18) |
| Partner Rx | Yes | Yes | Yes | Suppressive Rx if ≥6 recurrences/yr | Vaccine (9-45 years) |
Doxycycline for chlamydia — Azithromycin 1g single dose is NO LONGER first-line for chlamydia — doxycycline 100mg BD × 7 days is superior (especially for rectal infections).
Treat gonorrhea + chlamydia — Coinfection rate is 30-50% — always treat for both (ceftriaxone + doxycycline) even if only one is confirmed.
Syphilis in pregnancy — Penicillin is the ONLY effective treatment for syphilis in pregnancy. If penicillin-allergic, desensitize. Doxycycline is contraindicated (teratogenic).
VDRL vs FTA-ABS — VDRL/RPR = nontreponemal (screening, monitor treatment response — 4-fold decrease = success); FTA-ABS/TPPA = treponemal (confirmatory, positive for life, cannot monitor response).
Treatment of chlamydia — Doxycycline 100mg BD × 7 days
Treatment of gonorrhea — Ceftriaxone 500mg IM + doxycycline
Painless genital ulcer — Syphilis (chancre)
Grouped painful vesicles — HSV
Cauliflower-like lesions — HPV / Condyloma acuminata
| E |
|---|
| Doxycycline for chlamydia — Azithromycin 1g single dose is NO LONGER first-line for chlamydia — doxycycline 100mg BD × 7 days is superior (especially for rectal infections). |
| W |
|---|
| Treat gonorrhea + chlamydia — Coinfection rate is 30-50% — always treat for both (ceftriaxone + doxycycline) even if only one is confirmed. |
| P |
|---|
| Pearl — Treatment of chlamydia: Doxycycline 100mg BD × 7 days |
A 24-year-old sexually active woman presents with lower abdominal pain for 5 days, fever (38.5°C), and abnormal vaginal discharge. On exam, there is cervical motion tenderness (chandelier sign), adnexal tenderness, and purulent cervical discharge. She has an IUD in place placed 2 years ago.
Recognition Pattern — Lower abdominal pain + fever + cervical motion tenderness + adnexal tenderness + purulent discharge = PID. IUD is a risk factor (only in first 20 days after insertion). Minimum diagnostic criteria: cervical motion tenderness OR uterine tenderness OR adnexal tenderness.
Cervical motion tenderness (chandelier sign) + lower abdominal pain + fever = PID. Low threshold for diagnosis — treat empirically to prevent long-term complications (infertility, ectopic, chronic pain).
Low threshold for diagnosis — Don't wait for all criteria — just cervical motion tenderness + lower abdominal pain is enough to start treatment. Missing PID leads to infertility.
RUQ pain + PID — Fitz-Hugh-Curtis syndrome — perihepatitis from gonorrhea/chlamydia. Patient has RUQ pain but the source is pelvic. Always ask about STI risk.
IUD and PID — IUD increases PID risk only in first 20 days after insertion. After that, no increased risk. Don't remove IUD in mild-moderate PID — treat with antibiotics first.
14-day treatment — PID treatment must be 14 days total — don't stop early even if symptoms improve. Incomplete treatment leads to recurrence and chronic complications.
Minimum criteria for PID diagnosis — Cervical motion tenderness OR uterine tenderness OR adnexal tenderness
Most common cause of PID — Chlamydia trachomatis
Fitz-Hugh-Curtis syndrome — Perihepatitis (RUQ pain) from gonorrhea/chlamydia
Ruptured TOA management — Surgical emergency — exploratory laparotomy
| E |
|---|
| Low threshold for diagnosis — Don't wait for all criteria — just cervical motion tenderness + lower abdominal pain is enough to start treatment. Missing PID leads to infertility. |
| W |
|---|
| RUQ pain + PID — Fitz-Hugh-Curtis syndrome — perihepatitis from gonorrhea/chlamydia. Patient has RUQ pain but the source is pelvic. Always ask about STI risk. |
| P |
|---|
| Pearl — Minimum criteria for PID diagnosis: Cervical motion tenderness OR uterine tenderness OR adnexal tenderness |
A 30-year-old woman presents with thick, white, curdy vaginal discharge and severe vulvar itching for 4 days. She recently completed a course of amoxicillin for sinusitis. She is not sexually active. Vaginal pH is 4.2. KOH preparation shows pseudohyphae.
Recognition Pattern — Post-antibiotic + thick white curdy discharge + severe itching + normal pH (<4.5) + pseudohyphae on KOH = vulvovaginal candidiasis (C. albicans). Antibiotics disrupt normal flora → Candida overgrowth.
Cottage cheese discharge + severe itching + normal pH = candidiasis. Fishy odor + clue cells + pH >4.5 = BV. Frothy green + strawberry cervix + pH >4.5 = trichomoniasis.
| Bacterial Vaginosis | Vulvovaginal Candidiasis | Trichomoniasis | |
|---|---|---|---|
| Pathogen | Gardnerella vaginalis + anaerobes | Candida albicans (90%) | Trichomonas vaginalis (protozoan) |
| Vaginal pH | >4.5 | <4.5 (normal) | >4.5 |
| Discharge | Thin, gray-white, homogeneous | Thick, white, curdy (cottage cheese) | Yellow-green, frothy, malodorous |
| Odor | Fishy (worse after sex/menses) | None | Foul, fishy |
| Itching | Minimal | Severe vulvar itching/burning | Variable |
| Microscopy | Clue cells (epithelial + bacteria) | Pseudohyphae / budding yeast | Motile trichomonads |
| Cervix | Normal | Normal | Strawberry cervix (colpitis macularis) |
| Treat partner | No | No (unless balanitis) | YES (STI) |
| Pregnancy | Treat if symptomatic (preterm birth risk) | Topical azoles only (no fluconazole) | Metronidazole 2g PO (all trimesters) |
pH is key discriminator — Candidiasis has NORMAL pH (<4.5), BV and trichomoniasis have ELEVATED pH (>4.5). This is the single best differentiator.
Fluconazole in pregnancy — Fluconazole is teratogenic — DO NOT use in pregnancy. Use topical azoles (clotrimazole, miconazole) for candidiasis in pregnancy.
Treat partner — BV vs trich — BV and candidiasis: NO partner treatment (not STIs). Trichomoniasis: YES treat partner (STI). This is a classic exam discriminator.
Fishy odor + clue cells — Bacterial vaginosis
Cottage cheese + severe itching — Vulvovaginal candidiasis
Frothy green + strawberry cervix — Trichomoniasis
Normal vaginal pH — 3.8-4.5
Clue cells = what — Epithelial cells covered with bacteria (obscured borders)
| E |
|---|
| pH is key discriminator — Candidiasis has NORMAL pH (<4.5), BV and trichomoniasis have ELEVATED pH (>4.5). This is the single best differentiator. |
| W |
|---|
| Fluconazole in pregnancy — Fluconazole is teratogenic — DO NOT use in pregnancy. Use topical azoles (clotrimazole, miconazole) for candidiasis in pregnancy. |
| P |
|---|
| Pearl — Fishy odor + clue cells: Bacterial vaginosis |
A 38-year-old woman presents with heavy menstrual bleeding and pelvic pressure for 2 years. She has urinary frequency and feels a heavy sensation in her lower abdomen. On exam, the uterus is enlarged, irregular, firm, and mobile — corresponding to 16 weeks size. She desires future fertility.
Recognition Pattern — Reproductive-age woman + HMB + pelvic pressure + urinary frequency + enlarged irregular firm uterus = uterine fibroids. Estrogen/progesterone-dependent — grow during reproductive years, shrink after menopause.
Enlarged irregular firm uterus + HMB + pelvic pressure = fibroids until proven otherwise. Submucosal = most bleeding. Subserosal = most pressure symptoms. Pedunculated = risk of torsion.
Leiomyoma / Fibroid — Benign smooth muscle tumour of uterus (Pathology, exam)
Submucosal fibroid — Protrudes into uterine cavity → HMB, infertility, MOST symptomatic (exam, USMLE)
Intramural fibroid — Within myometrium → most common, bulk symptoms (exam)
Subserosal fibroid — Projects from outer surface → pressure, less bleeding (exam)
Pedunculated fibroid — Attached by stalk → torsion risk (subserosal) or prolapse (submucosal) (exam)
Red degeneration — Hemorrhagic infarction in pregnancy → acute pain, fever, leukocytosis (exam)
Submucosal = most bleeding — Submucosal fibroids protrude into the endometrial cavity — they cause the MOST bleeding and MOST fertility problems.
Myomectomy not hysterectomy — When fertility is desired, offer myomectomy (not hysterectomy). This is a classic exam point — 'young woman wants children, what surgery?'
Rapid growth postmenopause — Fibroids should shrink after menopause (estrogen-dependent). RAPID growth in postmenopausal woman = suspect leiomyosarcoma (rare but aggressive).
Red degeneration in pregnancy — Acute severe pain + fever + fibroid in pregnancy = red degeneration (hemorrhagic infarction). Treat CONSERVATIVELY — avoid surgery.
Fibroid type causing most bleeding — Submucosal (protrudes into cavity)
Definitive treatment for fibroids — Hysterectomy
Fertility-sparing surgery — Myomectomy
Acute pain in fibroid in pregnancy — Red degeneration (conservative management)
Why fibroids shrink after menopause — Estrogen and progesterone dependent
| E |
|---|
| Submucosal = most bleeding — Submucosal fibroids protrude into the endometrial cavity — they cause the MOST bleeding and MOST fertility problems. |
| W |
|---|
| Myomectomy not hysterectomy — When fertility is desired, offer myomectomy (not hysterectomy). This is a classic exam point — 'young woman wants children, what surgery?' |
| P |
|---|
| Pearl — Fibroid type causing most bleeding: Submucosal (protrudes into cavity) |
A 32-year-old woman presents with progressively worsening pelvic pain that starts a few days before her period and continues through. She also reports pain with intercourse and has been unable to conceive for 2 years. On exam, there is nodularity in the posterior fornix and a fixed retroverted uterus.
Recognition Pattern — Classic triad: Dysmenorrhea (progressive) + dyspareunia (deep) + dyschezia (painful bowel movements) + infertility = endometriosis. Nodularity in posterior fornix + fixed retroverted uterus are classic exam findings.
Progressive dysmenorrhea + deep dyspareunia + infertility = endometriosis until proven otherwise. The 3 Ds: Dysmenorrhea, Dyspareunia, Dyschezia. Laparoscopy is gold standard for diagnosis.
Endometriosis — Endometrial glands and stroma OUTSIDE the uterus (Pathology, exam)
Endometrioma — Chocolate cyst — ovarian endometriosis (ground glass on US) (Imaging, exam)
Adenomyosis — Endometrial glands WITHIN the myometrium (Pathology, exam)
Powder burn lesions — Classic black/blue lesions on laparoscopy (gunshot lesions) (exam, Surgery)
rASRM staging — Revised American Society for Reproductive Medicine — stages I-IV (Staging)
Stage ≠ Pain — Stage of endometriosis (rASRM I-IV) does NOT correlate with pain severity. A patient with stage I can have severe pain, stage IV may be asymptomatic.
Medical ≠ cure — Medical treatment only SUPPRESSES endometriosis — it does not cure it. Symptoms recur when treatment is stopped. Only definitive surgery (hysterectomy + BSO) is curative.
Medical helps pain, not fertility — Medical suppression for fertility is counterproductive because it suppresses ovulation. For fertility, do surgery (excision) then attempt natural conception or IVF.
Chocolate cyst — Endometriomas contain old blood (chocolate cyst). Ground glass appearance on US is diagnostic. Surgical removal if >4 cm.
Classic triad of endometriosis — Dysmenorrhea + Dyspareunia + Dyschezia (3 Ds)
Gold standard for diagnosis — Laparoscopy with biopsy
Definitive treatment — Hysterectomy with BSO
Ultrasound finding in endometrioma — Ground glass appearance (homogeneous low-level echoes)
Medical suppression for fertility — Does NOT help (suppresses ovulation)
| E |
|---|
| Stage ≠ Pain — Stage of endometriosis (rASRM I-IV) does NOT correlate with pain severity. A patient with stage I can have severe pain, stage IV may be asymptomatic. |
| W |
|---|
| Medical ≠ cure — Medical treatment only SUPPRESSES endometriosis — it does not cure it. Symptoms recur when treatment is stopped. Only definitive surgery (hysterectomy + BSO) is curative. |
| P |
|---|
| Pearl — Classic triad of endometriosis: Dysmenorrhea + Dyspareunia + Dyschezia (3 Ds) |
A 28-year-old woman presents with sudden onset of severe right-sided pelvic pain, nausea, and vomiting. She has a 6 cm ovarian cyst known from a prior ultrasound. On exam, she has a tender adnexal mass. Pain is constant and severe. Doppler shows arterial flow.
Recognition Pattern — Sudden severe unilateral pelvic pain + known ovarian mass + nausea/vomiting = ovarian torsion until proven otherwise. Doppler flow does NOT rule out torsion (intermittent torsion). 5-10 cm masses have highest torsion risk. Surgical emergency.
Sudden severe unilateral pelvic pain + adnexal mass + vomiting = ovarian torsion. Don't be reassured by normal Doppler (torsion can be intermittent). Highest risk: 5-10 cm, dermoid cysts, pregnancy, ovarian hyperstimulation.
| Functional Cyst | Mature Cystic Teratoma (Dermoid) | Fibroma | Ovarian Cancer | |
|---|---|---|---|---|
| Age | Reproductive age | <30 years (most common) | 30-50 years | 60-70 years (postmenopausal) |
| Character | Follicular/corpus luteum cyst | Contains all 3 germ layers (hair, teeth, sebum) | Solid benign tumor | Complex solid/cystic, septations |
| Sonography | Simple cyst, thin-walled, anechoic | Rokitansky nodule, fat-fluid level | Solid, hypoechoic | Thick septations, papillary projections, ascites |
| CA-125 | Normal | Normal | Normal | Elevated in 80% (epithelial) |
| Syndrome | None | None | Meigs syndrome (ascites + pleural effusion) | None |
| Management | Observe (resolves 1-2 cycles) | Cystectomy (torsion risk) | Cystectomy | Staging laparotomy + chemo |
Doppler does not rule out torsion — Normal Doppler flow does NOT exclude torsion — torsion can be intermittent. If clinical suspicion is high, proceed to surgery regardless of Doppler.
CA-125 in premenopausal — CA-125 is NOT useful in premenopausal women — too many false positives (endometriosis, fibroids, PID, pregnancy, menstruation).
Functional cysts anovulatory — Functional cysts should NOT occur in anovulatory women (PCOS, menopause). If a postmenopausal woman has a functional cyst, suspect other pathology.
Meigs syndrome — Ovarian fibroma + ascites + pleural effusion = Meigs syndrome. It is BENIGN — resolves after tumor removal. Not to be confused with malignant ascites.
Most common ovarian mass in reproductive age — Functional cyst (follicular)
Most common benign ovarian tumor <30 years — Mature cystic teratoma (dermoid)
Highest torsion risk mass size — 5-10 cm (dermoids especially)
Meigs syndrome — Ovarian fibroma + ascites + pleural effusion (benign)
Treatment of ovarian torsion — Detorsion (preserve ovary if viable)
| E |
|---|
| Doppler does not rule out torsion — Normal Doppler flow does NOT exclude torsion — torsion can be intermittent. If clinical suspicion is high, proceed to surgery regardless of Doppler. |
| W |
|---|
| CA-125 in premenopausal — CA-125 is NOT useful in premenopausal women — too many false positives (endometriosis, fibroids, PID, pregnancy, menstruation). |
| P |
|---|
| Pearl — Most common ovarian mass in reproductive age: Functional cyst (follicular) |
A 65-year-old para 4 woman presents with a sensation of a bulge in her vagina that worsens at the end of the day and improves when she lies down. She has difficulty emptying her bladder and needs to splint her vagina to have a bowel movement. She has a history of vaginal deliveries with large babies.
Recognition Pattern — Vaginal bulge worse with standing/end of day + improves lying down + splinting to defecate + vaginal childbirth history + menopause = pelvic organ prolapse. Symptoms worse at end of day due to gravity — classic distinguishing feature.
Vaginal bulge worse at end of day + improves lying down = pelvic organ prolapse. Most common cause: vaginal childbirth. POP-Q system for grading. First-line treatment for mild-moderate: conservative (Kegels, pessary).
Cystocele — Bladder descends into anterior vaginal wall (Anatomy)
Rectocele — Rectum bulges into posterior vaginal wall (Anatomy)
Enterocele — Small bowel herniates into vaginal apex (Anatomy)
Uterine prolapse — Uterus descends into vagina (Anatomy)
Vault prolapse — Top of vagina descends (post-hysterectomy) (Anatomy)
Colpocleisis — Obliterative surgery — close vaginal canal (elderly, not sexually active) (exam)
Sacrocolpopexy — Gold standard for vault prolapse repair (suspend vagina to sacrum) (exam)
Symptom worse end of day — Gravity worsens prolapse when standing throughout the day — symptoms improve when lying down. This is a classic differentiating feature from other pelvic pathology.
Sacrocolpopexy = gold standard — Sacrocolpopexy (suspend vaginal vault to sacral promontory) is the gold standard for vault prolapse repair with the lowest recurrence rate.
Pessary risks — Pessary left in too long can cause vaginal erosion, ulceration, and infection. Must be removed and cleaned regularly (every 3-6 months by provider).
Most common cause of POP — Vaginal childbirth
First-line treatment stage I-II — Conservative (Kegel exercises, pessary)
Gold standard for vault prolapse — Sacrocolpopexy
Obliterative surgery option — Colpocleisis (elderly, not sexually active)
Splinting to defecate — Rectocele
| E |
|---|
| Symptom worse end of day — Gravity worsens prolapse when standing throughout the day — symptoms improve when lying down. This is a classic differentiating feature from other pelvic pathology. |
| W |
|---|
| Sacrocolpopexy = gold standard — Sacrocolpopexy (suspend vaginal vault to sacral promontory) is the gold standard for vault prolapse repair with the lowest recurrence rate. |
| P |
|---|
| Pearl — Most common cause of POP: Vaginal childbirth |
A 52-year-old woman reports leaking urine when she coughs, sneezes, or exercises. She does not feel urgency before leaks. She had three vaginal deliveries. She is 3 years postmenopausal and not on HRT. Post-void residual is 40 mL.
Recognition Pattern — Leaks with increased intra-abdominal pressure (cough/sneeze/exercise) + NO urgency + vaginal childbirth history + menopause + normal PVR = stress urinary incontinence (urethral hypermobility / intrinsic sphincter deficiency).
Leaks when coughs/sneezes, no urgency = stress incontinence. Sudden strong urge + can't make it to toilet = urge incontinence (OAB). Constant dribbling + high PVR = overflow incontinence.
| Stress Incontinence | Urge Incontinence (OAB) | Overflow Incontinence | |
|---|---|---|---|
| Mechanism | Urethral hypermobility / intrinsic sphincter deficiency | Detrusor overactivity → involuntary bladder contraction | Bladder outlet obstruction / detrusor underactivity |
| Trigger | Cough, sneeze, laugh, exercise — ↑ intra-abdominal pressure | Sudden strong urge to void — may not make it to toilet | Bladder overdistension → constant dribbling |
| Symptoms | Leaks with ↑ pressure, NO urgency | Urgency, frequency, nocturia | Constant dribbling, incomplete emptying, weak stream |
| PVR | Normal (<50-100 mL) | Normal | Elevated (>200 mL) |
| First-line | Pelvic floor exercises (Kegels) × 8 weeks minimum | Bladder training + anticholinergics | Treat underlying cause; self-catheterization |
| Surgery | Mid-urethral sling (80-90% cure) | Botox detrusor injection (lasts 6-9 months) | Surgery if obstruction |
Kegels first for stress — First-line treatment for stress incontinence is pelvic floor exercises (Kegels), not surgery. Minimum 8 weeks for effect.
TVT sling is surgery — Mid-urethral sling (TVT/TOT) is the most common surgical treatment for stress incontinence — 80-90% cure rate. Complications: mesh erosion, retention, de novo urgency.
Overflow = high PVR — Overflow incontinence presents with constant dribbling, weak stream, and feeling of incomplete emptying. Key diagnostic finding: post-void residual >200 mL.
Stress incontinence trigger — Cough, sneeze, laugh — no urgency
Urge incontinence trigger — Sudden strong urge, frequency, nocturia
First-line stress incontinence — Kegel exercises (pelvic floor training)
Most common surgical treatment — Mid-urethral sling
| E |
|---|
| Kegels first for stress — First-line treatment for stress incontinence is pelvic floor exercises (Kegels), not surgery. Minimum 8 weeks for effect. |
| W |
|---|
| TVT sling is surgery — Mid-urethral sling (TVT/TOT) is the most common surgical treatment for stress incontinence — 80-90% cure rate. Complications: mesh erosion, retention, de novo urgency. |
| P |
|---|
| Pearl — Stress incontinence trigger: Cough, sneeze, laugh — no urgency |
A 45-year-old woman presents with postcoital bleeding for 3 months. She has not had a Pap smear in 8 years. On speculum exam, there is a visible exophytic lesion on the cervix that bleeds easily on contact. She has no pelvic pain or urinary symptoms.
Recognition Pattern — Postcoital bleeding + visible cervical lesion + no screening in >5 years = cervical cancer until proven otherwise. Most common symptom is postcoital bleeding. 70% are squamous cell carcinoma from transformation zone. HPV 16/18 cause 70% of cases.
Postcoital bleeding + visible cervical lesion = cervical cancer until proven otherwise. Take 10-20 years from HPV infection to invasive cancer. Slow progression allows screening to catch precancerous lesions (CIN).
CIN (Cervical Intraepithelial Neoplasia) — CIN 1 (mild) → CIN 2 (moderate) → CIN 3 (severe/carcinoma in situ) (Pathology, Screening)
Transformation zone — Junction of squamous + columnar epithelium — where most cancers arise (Anatomy, exam)
LEEP — Loop Electrosurgical Excision Procedure — excise CIN with electrified wire loop (Treatment)
HPV vaccination — Gardasil 9: types 6, 11, 16, 18, 31, 33, 45, 52, 58; age 9-45 (Prevention)
Co-testing — Pap + HPV cotesting every 5 years (age 30-65) (Screening)
Postcoital bleeding = cancer until proven — Postcoital bleeding is the most common presenting symptom of cervical cancer. Always examine cervix and do Pap smear — do not dismiss as benign.
HPV vaccine ≠ stop screening — HPV vaccination does NOT eliminate the need for cervical cancer screening. The vaccine covers 9 types, not all cancer-causing types.
HSIL on Pap = colposcopy — HSIL (high-grade squamous intraepithelial lesion) on Pap requires immediate referral for colposcopy with biopsy. Do not repeat Pap.
CIN 2-3 treatment — CIN 2-3 is precancerous and requires treatment (LEEP or cone biopsy). Do not observe like CIN 1 (which can regress).
Most common cervical cancer symptom — Postcoital bleeding
Most common histology — Squamous cell carcinoma (70%)
Cause of cervical cancer — Persistent high-risk HPV infection (16, 18)
HSIL on Pap — next step — Colposcopy with biopsy
Treatment CIN 2-3 — LEEP or cone biopsy
Best imaging for staging — MRI pelvis
| E |
|---|
| Postcoital bleeding = cancer until proven — Postcoital bleeding is the most common presenting symptom of cervical cancer. Always examine cervix and do Pap smear — do not dismiss as benign. |
| W |
|---|
| HPV vaccine ≠ stop screening — HPV vaccination does NOT eliminate the need for cervical cancer screening. The vaccine covers 9 types, not all cancer-causing types. |
| P |
|---|
| Pearl — Most common cervical cancer symptom: Postcoital bleeding |
A 62-year-old woman presents with vaginal bleeding for 2 weeks. She is 12 years postmenopausal and has not had any bleeding since menopause. She has a history of obesity (BMI 36) and hypertension. She has never taken HRT. Transvaginal ultrasound shows endometrial stripe of 8 mm.
Recognition Pattern — Postmenopausal bleeding (ANY bleeding after 12 months amenorrhea) = endometrial cancer until proven otherwise. Risk factors: obesity (unopposed estrogen), tamoxifen, Lynch syndrome, late menopause. Endometrial stripe <5 mm = low risk (<1% cancer); ≥5 mm needs sampling.
ANY postmenopausal bleeding = endometrial cancer until proven otherwise. Endometrial biopsy (Pipelle) is gold standard for diagnosis. Type I (endometrioid, estrogen-related, good prognosis) vs Type II (serous/clear cell, aggressive, poor prognosis).
Postmenopausal bleeding — Bleeding >12 months after amenorrhea — cancer until proven otherwise (exam, USMLE)
Pipelle biopsy — Office endometrial biopsy — 90% sensitive for cancer (Procedure)
Type I endometrial cancer — Endometrioid, estrogen-related, younger/obese, better prognosis (exam)
Type II endometrial cancer — Serous/clear cell, non-estrogen, older/thin, aggressive (exam)
Lynch syndrome (HNPCC) — MSH2/MLH1 mutation → 40-60% lifetime risk of endometrial cancer (exam)
Stripe <5 mm = low risk — Postmenopausal bleeding + endometrial stripe <5 mm on TVS = <1% risk of cancer — can observe. Stripe ≥5 mm needs biopsy regardless of appearance.
Obesity = unopposed estrogen — Obesity is the most important modifiable risk factor — adipose tissue converts androgens to estrogen → unopposed estrogen → endometrial hyperplasia → cancer.
Tamoxifen risk — Tamoxifen is a partial estrogen agonist in the endometrium → increased risk of endometrial cancer. Any bleeding on tamoxifen needs investigation.
OCPs protect — Combined OCPs DECREASE risk of endometrial cancer (progesterone protects endometrium). Never tell a patient OCPs cause endometrial cancer.
Most common presenting symptom — Postmenopausal bleeding (PMB)
Most important risk factor — Unopposed estrogen (obesity most important modifiable)
Gold standard for diagnosis — Endometrial biopsy (Pipelle)
Endometrial stripe threshold — <5 mm → <1% cancer risk; ≥5 mm → biopsy
Fertility-sparing treatment — High-dose progestin therapy
| E |
|---|
| Stripe <5 mm = low risk — Postmenopausal bleeding + endometrial stripe <5 mm on TVS = <1% risk of cancer — can observe. Stripe ≥5 mm needs biopsy regardless of appearance. |
| W |
|---|
| Obesity = unopposed estrogen — Obesity is the most important modifiable risk factor — adipose tissue converts androgens to estrogen → unopposed estrogen → endometrial hyperplasia → cancer. |
| P |
|---|
| Pearl — Most common presenting symptom: Postmenopausal bleeding (PMB) |
A 68-year-old woman presents with 3 months of progressive abdominal distension, early satiety, and pelvic pressure. She has lost weight unintentionally. On exam, there is ascites and a firm, fixed pelvic mass. She has a family history of breast cancer in her sister diagnosed at age 40.
Recognition Pattern — Postmenopausal woman + vague GI symptoms (bloating, early satiety) + pelvic mass + ascites + family history of breast cancer = ovarian cancer until proven otherwise. 75% diagnosed at stage III-IV (already spread). CA-125 is elevated in 80% but NOT for screening.
Postmenopausal woman with vague abdominal symptoms + pelvic mass + ascites = ovarian cancer. Most lethal gynecologic malignancy. Most important prognostic factor: residual disease after optimal debulking surgery.
Epithelial ovarian cancer — Serous (most common), mucinous, endometrioid, clear cell (Pathology, exam)
BRCA1/BRCA2 — BRCA1 → 40-50% ovarian Ca risk; BRCA2 → 20-30%; also breast cancer (Genetics, exam)
Optimal debulking — Cytoreduction to no visible residual disease — most important prognostic factor (Surgery, exam)
PARP inhibitors — Synthetic lethality in BRCA-mutated cancers (Treatment)
RRSO — Risk-reducing salpingo-oophorectomy at age 35-40 for BRCA carriers (Prevention)
CA-125 NOT for screening — CA-125 has poor sensitivity for early-stage ovarian cancer and poor specificity (elevated in endometriosis, fibroids, PID, pregnancy, menstruation). Do NOT use for screening.
Optimal debulking = key — The single most important prognostic factor in ovarian cancer is the amount of residual disease after debulking surgery. Optimal = no visible residual.
Most lethal gyn malignancy — Ovarian cancer is the most lethal gynecologic malignancy because 75% are diagnosed at Stage III-IV (vague symptoms, no effective screening).
Most lethal gynecologic malignancy — Ovarian cancer
Most important prognostic factor — Optimal debulking (no visible residual)
Standard chemotherapy — Carboplatin + paclitaxel
BRCA1 ovarian cancer risk — 40-50% lifetime
BRCA2 ovarian cancer risk — 20-30% lifetime
Prevention for BRCA carriers — RRSO at age 35-40
Why OCPs protect — Suppress ovulation (incessant ovulation hypothesis)
| E |
|---|
| CA-125 NOT for screening — CA-125 has poor sensitivity for early-stage ovarian cancer and poor specificity (elevated in endometriosis, fibroids, PID, pregnancy, menstruation). Do NOT use for screening. |
| W |
|---|
| Optimal debulking = key — The single most important prognostic factor in ovarian cancer is the amount of residual disease after debulking surgery. Optimal = no visible residual. |
| P |
|---|
| Pearl — Most lethal gynecologic malignancy: Ovarian cancer |
A 22-year-old woman requests contraception. She has regular periods, is sexually active with one partner, and has no medical conditions. She smokes occasionally. Her BMI is 24. She wants something she doesn't have to think about daily.
Recognition Pattern — Young healthy woman requesting LARC (long-acting reversible contraception). Options: IUD (copper or LNG-IUS) or implant. COCs are also appropriate if no contraindications (migraine with aura, smoker >35, DVT history, etc.).
When choosing contraception: efficacy (LARC > COC > barrier), compliance (IUD/implant = set-and-forget), contraindications (estrogen in COCs), STI protection (only condoms). Most effective reversible = IUD/implant.
| COCs | POP (Progestin-only) | DMPA (Depo) | LNG-IUS | Copper IUD | Implant | |
|---|---|---|---|---|---|---|
| Perfect/typical use | >99% / 91% | 99% / 91% | >99% / 94% | >99% / >99% | >99% / >99% | >99% / >99% |
| Duration | Monthly (21/7) | Monthly | Every 3 months | 5-7 years | 10-12 years | 3-5 years |
| Period effect | Regular, lighter | Irregular bleeding | Irregular → amenorrhea | Lighter → amenorrhea 20% | Heavier, longer | Lighter → amenorrhea |
| Estrogen | Yes | No | No | No | No | No |
| Breastfeeding safe | No | Yes | Yes | Yes | Yes | Yes |
| Notable benefit | Regulates cycles, acne, hirsutism | Safe breastfeeding | Reduces seizures, sickle cell crises | Treats HMB, endometriosis | Non-hormonal, EC | Long-acting, set-and-forget |
LARC most effective reversible — IUDs and implant are the most effective reversible contraceptives (>99%) — superior to OCPs, patch, ring. Not 'permanent' like sterilization.
IUD in nulliparous — Nulliparous women CAN use IUDs. No increased risk of future infertility. The 'IUD causes infertility' myth is outdated and harmful.
Doxycycline for chlamydia — Azithromycin is NO LONGER first-line for chlamydia — doxycycline 100mg BD × 7 days is now recommended (superior efficacy, especially for rectal infections).
Missed pill rule — 1 pill missed: take ASAP, continue pack. 2+ missed: take last missed pill, use backup × 7 days, consider EC if unprotected sex in prior 5 days.
Most effective reversible contraception — LARC — IUD or implant (>99%)
Only contraception with STI protection — Condoms (male and female)
Most effective emergency contraception — Copper IUD (>99%, insert within 5 days)
How Plan B works — Delays/prevents ovulation (NOT abortion)
Absolute COC contraindications — DVT, smoker >35, migraine with aura, breast cancer, liver disease
| E |
|---|
| LARC most effective reversible — IUDs and implant are the most effective reversible contraceptives (>99%) — superior to OCPs, patch, ring. Not 'permanent' like sterilization. |
| W |
|---|
| IUD in nulliparous — Nulliparous women CAN use IUDs. No increased risk of future infertility. The 'IUD causes infertility' myth is outdated and harmful. |
| P |
|---|
| Pearl — Most effective reversible contraception: LARC — IUD or implant (>99%) |
A 51-year-old woman presents with hot flashes occurring 8-10 times per day, night sweats disrupting sleep, and vaginal dryness causing pain during intercourse. She had her last menstrual period 14 months ago. She has no history of breast cancer or VTE. She has a uterus.
Recognition Pattern — Perimenopausal woman >45 + amenorrhea ×12 months + vasomotor symptoms (hot flashes, night sweats) + genitourinary syndrome (vaginal dryness, dyspareunia) = menopause. Clinical diagnosis — no lab tests needed if typical presentation.
Amenorrhea ×12 months + hot flashes + night sweats + age >45 = menopause (clinical diagnosis). FSH only needed if age <45 or atypical presentation. Most effective treatment for hot flashes = HRT (estrogen + progestin if uterus present).
Menopause — 12 months amenorrhea + ovarian follicle depletion (Definition)
Perimenopause — Transition period before final menses (irregular cycles, vasomotor symptoms) (exam)
Genitourinary syndrome of menopause — Vaginal atrophy, dryness, dyspareunia, UTIs due to estrogen deficiency (exam)
WHI study — Women's Health Initiative — showed combined HRT risks (breast cancer, VTE, stroke, CHD) (Evidence)
Window of opportunity — Start HRT <10 years postmenopause OR age <60 for cardiovascular benefit (exam)
Vasomotor symptoms — Hot flashes and night sweats — affect 80% of women, last 1-2 min, may persist 5-10 years (exam)
No lab needed for menopause — Menopause is a CLINICAL diagnosis in a woman >45 with amenorrhea ×12 months and typical symptoms. FSH is only for atypical presentation (age <45, unexplained symptoms).
Uterus = add progestin — Unopposed estrogen in a woman with a uterus causes endometrial hyperplasia → cancer. Always add progestin. If post-hysterectomy, estrogen-only is fine.
HRT window of opportunity — HRT has cardiovascular benefit if STARTED <10 years postmenopause or age <60. Starting after 60/10+ years increases cardiovascular risk. Timing matters.
Diagnosis of menopause (typical) — Clinical — amenorrhea ×12 months + symptoms
Most effective treatment for hot flashes — HRT (estrogen ± progestin)
Why add progestin to estrogen — Protects endometrium from hyperplasia/cancer
Post-hysterectomy — need progestin? — No (no endometrium to protect)
Non-hormonal hot flash treatment — SSRIs/SNRIs (paroxetine, venlafaxine), gabapentin
| E |
|---|
| No lab needed for menopause — Menopause is a CLINICAL diagnosis in a woman >45 with amenorrhea ×12 months and typical symptoms. FSH is only for atypical presentation (age <45, unexplained symptoms). |
| W |
|---|
| Uterus = add progestin — Unopposed estrogen in a woman with a uterus causes endometrial hyperplasia → cancer. Always add progestin. If post-hysterectomy, estrogen-only is fine. |
| P |
|---|
| Pearl — Diagnosis of menopause (typical): Clinical — amenorrhea ×12 months + symptoms |
A 24-year-old woman presents with a painless, mobile, rubbery breast mass she noticed 2 weeks ago. She is not on any medications and has no family history of breast cancer. Ultrasound shows a well-defined, hypoechoic, oval mass with parallel orientation.
Recognition Pattern — Young woman <30 + painless mobile rubbery mass + well-defined hypoechoic oval mass on US = fibroadenoma (most common benign breast tumor). Ultrasound is first-line imaging in women <30 (dense breast tissue).
Mobile rubbery breast mass in young woman = fibroadenoma. Bilateral lumpy breast pain with menses = fibrocystic changes. Bloody nipple discharge = intraductal papilloma. Painful mass in breastfeeding = mastitis/abscess.
First imaging <30 = US — In women <30 with a breast mass, ultrasound is first-line (dense breast tissue limits mammogram sensitivity). Mammogram is first-line in women >40.
Don't stop breastfeeding — Mastitis should NOT stop breastfeeding — continuing helps drain the infected milk and is safe for the baby. Only stop if abscess requires I&D.
Bloody nipple discharge — Bloody nipple discharge from a single duct suggests intraductal papilloma (benign) but papillary carcinoma can present similarly — needs surgical excision.
Most common benign breast condition — Fibrocystic changes
Most common benign breast tumor — Fibroadenoma
Mobile rubbery mass in young woman — Fibroadenoma
Bloody nipple discharge — Intraductal papilloma (needs excision)
First imaging <30 with breast mass — Ultrasound
| E |
|---|
| First imaging <30 = US — In women <30 with a breast mass, ultrasound is first-line (dense breast tissue limits mammogram sensitivity). Mammogram is first-line in women >40. |
| W |
|---|
| Don't stop breastfeeding — Mastitis should NOT stop breastfeeding — continuing helps drain the infected milk and is safe for the baby. Only stop if abscess requires I&D. |
| P |
|---|
| Pearl — Most common benign breast condition: Fibrocystic changes |
A 48-year-old woman presents for routine health maintenance. She has no breast symptoms. Her mother was diagnosed with breast cancer at age 52. She has no prior history of breast disease or chest radiation. She asks about when to start mammography.
Recognition Pattern — Average-risk woman (only one second-degree relative) → start mammogram at age 40-50 depending on guideline. USPSTF: biennial starting 50. ACS: annual starting 45 (option at 40). High-risk (BRCA, strong family history, chest radiation): annual mammo + MRI starting 30.
Breast cancer screening: start at 40-50 (average risk). If high risk (BRCA, strong family history, chest radiation) → annual mammogram + MRI starting age 30. BSE not recommended for screening (no mortality benefit).
BSE not recommended — Breast self-examination (BSE) is NOT recommended for screening — studies show no mortality benefit but increased biopsies and anxiety. Breast awareness is recommended instead.
Screening interval varies — USPSTF says biennial (every 2 years), ACS says annual. Know both for exams. The important point: screening reduces breast cancer mortality.
BRCA screening intensification — BRCA carriers need annual mammogram + MRI starting at age 30, not just mammogram. MRI is more sensitive in dense breasts.
Average-risk mammogram start — Age 40-50 (varies by guideline)
Average-risk mammogram frequency — Every 1-2 years (varies)
High-risk screening — Annual mammogram + MRI starting age 30
BRCA breast cancer risk — 45-70% lifetime
BSE for screening — Not recommended (no mortality benefit)
| E |
|---|
| BSE not recommended — Breast self-examination (BSE) is NOT recommended for screening — studies show no mortality benefit but increased biopsies and anxiety. Breast awareness is recommended instead. |
| W |
|---|
| Screening interval varies — USPSTF says biennial (every 2 years), ACS says annual. Know both for exams. The important point: screening reduces breast cancer mortality. |
| P |
|---|
| Pearl — Average-risk mammogram start: Age 40-50 (varies by guideline) |
A 55-year-old woman reports pain with intercourse that makes her avoid sexual activity. She describes the pain as burning at the vaginal opening during penetration. She is 7 years postmenopausal and not on any hormones. She has no history of pelvic surgery or radiation.
Recognition Pattern — Postmenopausal woman + superficial dyspareunia (pain at vaginal opening) + vaginal dryness + no other cause = genitourinary syndrome of menopause (vulvovaginal atrophy from estrogen deficiency). Treat with vaginal estrogen.
Superficial dyspareunia = vaginal atrophy, vulvodynia, infection. Deep dyspareunia = endometriosis, PID, ovarian cysts. Most common female sexual complaint: low desire (HSDD). Use PLISSIT model for history.
Superficial vs deep — Superficial dyspareunia (pain at entry) = vulvar/vaginal cause (atrophy, vulvodynia, infection, vaginismus). Deep dyspareunia = pelvic cause (endometriosis, PID, ovarian cysts). Location tells you the origin.
Vaginal estrogen safety — Vaginal estrogen has very low systemic absorption — it is safe even in women with breast cancer history (discuss with oncologist). No progestin needed.
Most common female sexual complaint — Low desire (HSDD)
Superficial dyspareunia causes — Vaginal atrophy, vulvodynia, infection, vaginismus
Deep dyspareunia causes — Endometriosis, PID, ovarian cysts
Dyspareunia in menopause — Vaginal atrophy (treat with vaginal estrogen)
Treatment for vaginismus — Pelvic floor PT + vaginal dilators
| E |
|---|
| Superficial vs deep — Superficial dyspareunia (pain at entry) = vulvar/vaginal cause (atrophy, vulvodynia, infection, vaginismus). Deep dyspareunia = pelvic cause (endometriosis, PID, ovarian cysts). Location tells you the origin. |
| W |
|---|
| Vaginal estrogen safety — Vaginal estrogen has very low systemic absorption — it is safe even in women with breast cancer history (discuss with oncologist). No progestin needed. |
| P |
|---|
| Pearl — Most common female sexual complaint: Low desire (HSDD) |
Fishy odor + clue cells — Bacterial vaginosis
Cottage cheese discharge + severe itching — Vulvovaginal candidiasis
Frothy green + strawberry cervix — Trichomoniasis
Postcoital bleeding → suspect — Cervical cancer (until proven otherwise)
Any postmenopausal bleeding → suspect — Endometrial cancer (until proven otherwise)
Progressive dysmenorrhea + dyspareunia + infertility — Endometriosis
Sudden severe pelvic pain + mass + vomiting — Ovarian torsion
Oligomenorrhea + hirsutism + obesity — PCOS
Mobile rubbery breast mass in young woman — Fibroadenoma
Red degeneration — Fibroid infarction in pregnancy (conservative Rx)
Chandelier sign — Severe cervical motion tenderness (PID)
Sister Mary Joseph nodule — Periumbilical metastasis (intra-abdominal malignancy)
| P |
|---|
| Pearl — Fishy odor + clue cells: Bacterial vaginosis |
Correct: B) Endometrial biopsy (Pipelle)
Concept: Endometrial stripe threshold in postmenopausal bleeding Interpretation
Why B: The endometrial stripe threshold is <5 mm → <1% cancer risk; ≥5 mm → biopsy regardless of appearance. At 6 mm, sampling is mandatory.
Discriminator: The source pairs this with the Top-MCQ-pearl stack — the threshold is binary, not graded; a 6 mm stripe is a biopsy, not a rescan.
| A) Repeat ultrasound in 6-8 weeks | An endometrial stripe ≥5 mm already crosses the biopsy threshold; observation is inappropriate for postmenopausal bleeding. |
| C) Start cyclic progestin and re-scan in 3 months | Empiric hormones never substitute for tissue diagnosis in postmenopausal bleeding. |
| D) MRI pelvis for local staging | MRI stages a proven cancer; it is not the first diagnostic step in the postmenopausal bleeding workup. |
| E) Reassure and schedule routine screening | Bleeding after 12 months of amenorrhea is cancer until proven otherwise — it is never merely observed. |
Trap: Borderline stripes (5-6 mm) tempt reassurance, but the rule is binary: <5 mm observe, ≥5 mm sample.
Future alert: Office Pipelle biopsy first; hysteroscopy with D&C if inadequate or not tolerated.
Correct: C) Constitutional delay
Concept: Most common cause of primary amenorrhea Recall
Why C: Constitutional delay is the most common cause of primary amenorrhea — a diagnosis of exclusion supported by family history of late menarche.
Discriminator: The source lists this as the single most commonly tested 'most common' fact in the prelude, ahead of Turner and CAIS.
| A) Turner syndrome (45,X) | A classic hypergonadotropic cause, but far from the most common cause of primary amenorrhea. |
| B) Complete androgen insensitivity syndrome | A well-known 46,XY cause with absent uterus, but rare in prevalence terms. |
| D) MRKH syndrome (Müllerian agenesis) | Important but uncommon; constitutional delay outnumbers it. |
| E) Kallmann syndrome | A hypogonadotropic cause with anosmia; uncommon. |
Trap: Do not pick the most dramatic syndrome (Turner/CAIS) — the exam targets 'most common', and that is constitutional delay.
Future alert: If growth and secondary sexual characteristics are appropriate, reassure and follow growth charts.
Correct: D) Urine or serum β-hCG (pregnancy test)
Concept: AUB — pregnancy test is the FIRST step Interpretation
Why D: Every reproductive-age woman with AUB gets a pregnancy test first — ectopic, miscarriage, and molar pregnancy can all present exactly as AUB.
Discriminator: The PALM-COEIN classification applies only after pregnancy is excluded; β-hCG is cheap, immediate, and completely changes management if positive.
| A) Transvaginal ultrasound | Imaging follows exclusion of pregnancy — ectopic, miscarriage, and molar pregnancy are all missed by scanning first. |
| B) Endometrial biopsy | Indicated at ≥45 years or with risk factors (obesity, PCOS, Lynch, unopposed estrogen) — not before pregnancy is excluded. |
| C) Coagulation panel (PT, aPTT, vWF) | Relevant because HMB began at menarche (suggests von Willebrand disease), but it is not the FIRST test. |
| E) TSH and prolactin | Endocrine workup comes later in the algorithm, not first. |
Trap: The vignette plants HMB since menarche to tempt a coagulopathy workup — the first step is still the pregnancy test.
Future alert: If negative: CBC, TVS, and endometrial biopsy if ≥45 years or risk factors; then PALM vs COEIN.
Correct: E) Tranexamic acid 1-1.5 g TDS during menses
Concept: Medical management of HMB — TXA vs OCPs Interpretation
Why E: Tranexamic acid reduces menstrual bleeding by 40-50% and is the first-line medical agent for acute HMB; OCPs are for cycle regulation.
Discriminator: The source is explicit: 'Tranexamic acid is first-line medical, not OCPs (OCPs are for cycle regulation, not acute bleeding reduction).'
| A) Combined oral contraceptive pills | OCPs regulate cycles and reduce bleeding long-term, but cycle regulation is not acute bleeding reduction — TXA is first-line medical. |
| B) LNG-IUS (Mirena) | Excellent long-term reduction (~90% at 6 months), but it is a device, not the first-line medical agent for acute loss. |
| C) GnRH agonist | Reserved for pre-operative use or fibroid shrinkage — suppresses estrogen rather than directly reducing bleeding. |
| D) Endometrial ablation | A surgical option — and contraindicated when future fertility is desired. |
Trap: Exam writers make OCPs the tempting 'regulation' answer — the question asks about acute loss, and that is TXA.
Future alert: If fertility is not immediately desired and bleeding persists, escalate to LNG-IUS; surgical options if medical therapy fails.
Correct: A) Age ≥45 years (or any age with risk factors such as obesity, PCOS, Lynch, unopposed estrogen)
Concept: AUB — endometrial biopsy threshold (age/risk, not stripe) Recall
Why A: Endometrial biopsy is indicated at ≥45 years OR any age with risk factors (obesity, PCOS, Lynch, unopposed estrogen) — never rely on ultrasound alone.
Discriminator: Obesity gives this patient unopposed estrogen; she qualifies by age and by BMI, making watchful waiting unsafe.
| B) Only if the endometrial stripe is ≥10 mm | The biopsy threshold is age/risk-based, not stripe-based — a normal stripe does not exclude pathology at this age. |
| C) Only after failure of medical management | Tissue diagnosis precedes long-term medical therapy at this age; never treat blind. |
| D) Only if bleeding requires transfusion | Bleeding severity does not gate cancer screening — age and risk factors do. |
| E) All women with AUB regardless of age | Young women without risk factors do not routinely need biopsy. |
Trap: The source warns against relying on ultrasound alone — imaging can look reassuring while hyperplasia or cancer is present.
Future alert: Office Pipelle biopsy; hysteroscopy + D&C if inadequate or not tolerated.
Correct: B) Complete androgen insensitivity syndrome (CAIS)
Concept: Primary amenorrhea — absent uterus: karyotype decides, 46,XY = CAIS Interpretation
Why B: Primary amenorrhea + normal breasts + no uterus → karyotype decides: 46,XY = CAIS (testes present, androgen-insensitive → female phenotype); 46,XX = MRKH.
Discriminator: Testes produce testosterone, but androgen insensitivity prevents virilization — hence preserved breast tissue (estrogen) with sparse pubic/axillary hair (androgen-dependent).
| A) MRKH syndrome (Müllerian agenesis) | MRKH is 46,XX with normal ovaries — the 46,XY karyotype excludes it. |
| C) Turner syndrome (45,X) | Turner gives streak gonads, short stature, and webbed neck — normal breast development does not fit. |
| D) Functional hypothalamic amenorrhea | A eugonadotropic/hypogonadotropic cause with a normal uterus — impossible with an absent uterus. |
| E) Asherman syndrome | Intrauterine adhesions follow D&C and require a prior endometrium — absent uterus excludes it. |
Trap: Do not stop at 'absent uterus' — the karyotype is the discriminator, and normal breasts steer toward CAIS rather than Turner.
Future alert: Gonadectomy after puberty (malignancy risk in abdominal testes); estrogen replacement; psychosexual support.
Correct: C) Drug-induced hyperprolactinemia (metoclopramide)
Concept: Secondary amenorrhea + galactorrhea — drug-induced hyperprolactinemia Analysis
Why C: Medications are the most common cause of hyperprolactinemia (antipsychotics, metoclopramide, domperidone). Metoclopramide is a dopamine antagonist → disinhibited prolactin secretion.
Discriminator: 100-200 ng/mL with an offending drug points to drug effect; >200 ng/mL without drugs points to prolactinoma. Always check the medication list before MRI.
| A) Prolactinoma (macroprolactinoma) | Prolactin >200 ng/mL without an offending drug suggests prolactinoma — here a dopamine antagonist explains the level. |
| B) Primary hypothyroidism | High TRH stimulates prolactin, but TSH is normal in this patient, excluding it. |
| D) Sheehan syndrome | Pituitary necrosis follows massive postpartum hemorrhage — the history does not fit. |
| E) Polycystic ovary syndrome | PCOS has normal prolactin; galactorrhea is not a feature. |
Trap: The mid-range prolactin is deliberate — resist the 'prolactinoma >200' reflex; the drug is the story.
Future alert: Stop or replace metoclopramide and recheck prolactin; MRI pituitary with contrast if the level remains >100 ng/mL.
Correct: D) Excess prostaglandin F2α → uterine hypercontractility and ischemia
Concept: Primary dysmenorrhea mechanism — prostaglandin F2α Recall
Why D: Endometrial breakdown releases prostaglandin F2α → uterine hypercontractility + ischemia → pain that STARTS WITH flow, not before.
Discriminator: This is why NSAIDs are most effective started 1-2 days BEFORE menses — preventing prostaglandin buildup rather than treating it.
| A) Endometrial glands within the myometrium | That describes adenomyosis — a cause of SECONDARY dysmenorrhea in older, often parous women. |
| B) Endometriosis implants outside the uterus | Endometriosis is a secondary cause; her young age, normal exam, and NSAID response fit primary dysmenorrhea. |
| C) Cervical stenosis causing outflow obstruction | Outflow obstruction is structural and secondary, not the mechanism of primary dysmenorrhea. |
| E) Elevated basal body temperature | Irrelevant to dysmenorrhea physiology. |
Trap: Pain starting with flow = prostaglandin-mediated primary dysmenorrhea in a young woman with a normal exam.
Future alert: NSAIDs ± combined OCPs; if refractory despite normal exam, laparoscopy for endometriosis.
Correct: E) Adenomyosis (endometrial glands within the myometrium)
Concept: Adenomyosis vs endometriosis — boggy uterus Interpretation
Why E: Boggy, symmetrically enlarged uterus + progressive dysmenorrhea + heavy bleeding = adenomyosis (endometrial glands IN the myometrium).
Discriminator: Endometriosis lives outside the uterus; adenomyosis lives inside the myometrium — the source contrasts them as a classic trap.
| A) Endometriosis | Endometriosis is glands OUTSIDE the uterus — classically dysmenorrhea + dyspareunia + infertility with fornix nodularity, not a boggy uterus. |
| B) Submucosal fibroid | Fibroids give an irregular FIRM uterus; the boggy symmetric enlargement points to adenomyosis. |
| C) Endometrioma | An ovarian chocolate cyst — no diffuse uterine enlargement. |
| D) PID | Infection causes cervical motion tenderness and fever, not a boggy enlarged uterus with heavy bleeding. |
Trap: 'Boggy uterus' is the code word that redirects from endometriosis to adenomyosis.
Future alert: TVS/MRI to confirm; medical suppression (progestins, LNG-IUS) or hysterectomy if definitive.
Correct: A) 2 of 3: oligo/anovulation + clinical or biochemical hyperandrogenism + polycystic ovarian morphology
Concept: PCOS — Rotterdam criteria (2 of 3) Recall
Why A: Rotterdam: 2 of 3 — oligo/anovulation, hyperandrogenism (clinical or biochemical), PCO morphology. PCO on ultrasound alone ≠ PCOS.
Discriminator: The source stresses that polycystic ovaries exist in 20-30% of healthy women — the criteria exist precisely to prevent overdiagnosis.
| B) Hyperandrogenism + polycystic morphology + elevated LH:FSH ratio | LH:FSH >2 is classic but explicitly NOT diagnostic of PCOS. |
| C) Oligomenorrhea + acanthosis nigricans + obesity | These are associations of insulin resistance, not diagnostic criteria. |
| D) Polycystic ovarian morphology alone | PCO morphology is found in 20-30% of normal women — never sufficient alone. |
| E) Oligo/anovulation + hirsutism + infertility | Infertility is a consequence, not a criterion. |
Trap: The LH:FSH ratio is the classic distractor — 'classic but NOT diagnostic'.
Future alert: Confirm with androgen profile; rule out virilizing tumor or CAH if onset is rapid.
Correct: B) Letrozole 2.5-7.5 mg
Concept: PCOS — first-line ovulation induction is letrozole Recall
Why B: Letrozole is first-line for ovulation induction in PCOS — superior to clomiphene, with higher live birth rates and lower multiple pregnancy risk.
Discriminator: The source states it plainly: 'Letrozole ... FIRST-LINE for ovulation induction (superior to clomiphene in PCOS)'; weight loss may restore ovulation first if BMI >30.
| A) Clomiphene citrate 50-150 mg days 3-7 | An alternative if letrozole is unavailable — but letrozole is superior (higher live birth, lower multiple pregnancy risk). |
| C) Metformin monotherapy | Metformin is adjunctive (BMI >25 or impaired glucose tolerance), not first-line induction. |
| D) Combined OCPs for 3 cycles then stop | Contraception cannot induce ovulation. |
| E) Immediate IVF | IVF follows failed oral agents or other infertility factors — it is not the first step. |
Trap: Clomiphene is the outdated reflex — the updated pearl is letrozole.
Future alert: If anovulation persists, add metformin, consider gonadotropins, then IVF.
Correct: C) Dopamine agonist — cabergoline (preferred) or bromocriptine
Concept: Prolactinoma — first-line treatment: dopamine agonist Recall
Why C: Dopamine agonists are first-line; cabergoline is preferred over bromocriptine — twice-weekly dosing, better tolerated, normalizes prolactin in 80-90%.
Discriminator: Surgery and radiation sit at the resistant end; medical therapy effectively shrinks micro- and macroadenomas.
| A) Transsphenoidal adenomectomy | Surgery is reserved for dopamine-agonist failure/intolerance, visual compromise, or apoplexy — not first-line. |
| B) Radiotherapy | Rarely needed; for resistant or residual tumors only. |
| D) Observe with annual MRI | Galactorrhea + amenorrhea with a confirmed adenoma warrants treatment, not observation. |
| E) Prolactin-lowering diet | No dietary therapy exists for prolactinomas. |
Trap: Bromocriptine is a valid agonist, but the preferred agent is cabergoline — and surgery is not first-line.
Future alert: Stop the dopamine agonist once pregnancy is confirmed unless macroadenoma with visual concerns.
Correct: D) Treat the hypothyroidism and recheck prolactin
Concept: Hyperprolactinemia from hypothyroidism — treat thyroid before MRI Interpretation
Why D: Primary hypothyroidism → elevated TRH → stimulates prolactin. 'Treat the thyroid first before doing MRI for prolactinoma.'
Discriminator: TSH 22 (elevated) + prolactin 92 is precisely the pattern the source warns about: check TSH before MRI.
| A) MRI pituitary with contrast | Do not image the pituitary before excluding hypothyroidism — elevated TRH stimulates prolactin and resolves with thyroid replacement. |
| B) Start cabergoline | Dopamine agonists treat prolactinoma, not TRH-driven hyperprolactinemia — thyroid replacement is the fix. |
| C) Order karyotype | No role in acquired secondary amenorrhea with galactorrhea. |
| E) Start combined OCPs for cycle regulation | Hormonal bleeding does not address the underlying pituitary-thyroid axis. |
Trap: The galactorrhea-prolactin reflex says 'MRI' — the elevated TSH is the giveaway that this is thyroid, not pituitary.
Future alert: Levothyroxine replacement; recheck prolactin and menstrual cycles.
Correct: E) Semen analysis
Concept: Infertility — first test is semen analysis Recall
Why E: Semen analysis is the easiest, cheapest, and least invasive first test in the infertility workup; collected after 2-5 days of abstinence.
Discriminator: Then assess ovulation (day 21 progesterone ≥10 ng/mL), tubal patency (HSG day 7-10), and reserve if >35 years.
| A) Hysterosalpingography | Assesses tubes and cavity — but the first test is the easy, non-invasive semen sample. |
| B) Day 21 progesterone | Confirms ovulation once male factor is cleared — not the first step. |
| C) AMH + day 3 FSH | Ovarian reserve testing matters over 35 years, but comes after the basic first-line tests. |
| D) Laparoscopy | Reserved for suspected endometriosis — invasive and late. |
Trap: Couple presentations tempt a 'test both at once' strategy — the algorithm still starts with semen analysis.
Future alert: If abnormal → urology; if normal → ovulation, HSG, then cause-based treatment (IUI/IVF).
Correct: A) Ovulation has occurred
Concept: Day 21 progesterone — confirms ovulation, not pregnancy Recall
Why A: Progesterone ≥10 ng/mL on day 21 of a 28-day cycle confirms ovulation — 'measures ovulation, NOT pregnancy.'
Discriminator: If cycles are irregular, time the draw 7 days before expected menses.
| B) Pregnancy | Day-21 progesterone assesses the luteal phase, not pregnancy — a hCG test does that. |
| C) Tubal patency | Tubes are assessed by HSG, not progesterone. |
| D) Adequate ovarian reserve | Reserve = day 3 FSH, AMH, and antral follicle count. |
| E) A luteal phase defect requiring treatment | ≥10 ng/mL is a NORMAL ovulatory value, not a defect. |
Trap: 'Day 21 progesterone' sounds like an early pregnancy test — the pearl is that it proves ovulation only.
Future alert: If anovulatory, treat the cause (e.g., letrozole for PCOS).
Correct: B) Doxycycline 100 mg PO BD × 7 days
Concept: Chlamydia — doxycycline is now first-line Recall
Why B: Doxycycline 100 mg BD × 7 days is now first-line for chlamydia — superior to single-dose azithromycin, especially for rectal infection.
Discriminator: Test of cure only if pregnant or non-adherent; retest in 3 months given the high reinfection rate.
| A) Azithromycin 1 g single dose | NO LONGER first-line — doxycycline is superior, especially for rectal infections. |
| C) Ceftriaxone 500 mg IM single dose | The gonorrhea component of coinfection treatment — not chlamydia monotherapy. |
| D) Benzathine penicillin G 2.4 million U IM | The syphilis regimen. |
| E) Metronidazole 500 mg PO BD × 7 days | Covers anaerobes and trichomoniasis — not chlamydia. |
Trap: Azithromycin single dose is the outdated reflex — the exam wants doxycycline.
Future alert: Retest at 3 months; screen and treat partner(s); report to public health.
Correct: C) Treponema pallidum (primary syphilis)
Concept: STI ulcer — painless chancre = primary syphilis Interpretation
Why C: Painless chancre (primary syphilis) → VDRL/RPR screen, FTA-ABS/TPPA confirm; treat with benzathine penicillin G 2.4 million U IM.
Discriminator: The painless solitary ulcer with clean edges and a firm base is the classic 'do not miss' syphilis presentation.
| A) Herpes simplex virus | HSV gives painful grouped vesicles on an erythematous base — a painless solitary chancre is syphilis. |
| B) Human papillomavirus | HPV causes cauliflower-like warts, not ulcers. |
| D) Neisseria gonorrhoeae | Gonorrhea presents as cervicitis or discharge, not a genital ulcer. |
| E) Chlamydia trachomatis | Chlamydia is usually asymptomatic or mucopurulent cervicitis — no ulcer. |
Trap: Pain is the discriminator: painless chancre = syphilis; painful grouped vesicles = HSV.
Future alert: RPR titer at diagnosis; expect a 4-fold decrease by 6-12 months as evidence of treatment success.
Correct: D) Diagnose PID and start empiric antibiotics
Concept: PID — minimum diagnostic criteria: treat on one finding Interpretation
Why D: Minimum criteria: cervical motion tenderness OR uterine tenderness OR adnexal tenderness — a single one suffices to start empiric treatment. Low threshold prevents long-term complications.
Discriminator: The source is explicit: 'just cervical motion tenderness + lower abdominal pain is enough to start treatment. Missing PID leads to infertility.'
| A) Wait for fever ≥38 °C and purulent discharge before treating | Minimum criteria are cervical motion tenderness OR uterine tenderness OR adnexal tenderness — waiting worsens tubal outcomes. |
| B) Treat only if chlamydia/gonorrhea NAAT returns positive | Never delay treatment for results — empiric therapy prevents tubal damage. |
| C) Discharge with analgesia and review in 1 week | Untreated PID causes infertility, ectopic pregnancy, and chronic pelvic pain. |
| E) Start combined OCPs to reduce dysmenorrhea | Contraception does not treat infection. |
Trap: The vignette deliberately withholds fever and purulent discharge — the chandelier sign alone gates treatment.
Future alert: Outpatient: ceftriaxone 500 mg IM + doxycycline + metronidazole × 14 days; re-examine in 48-72 hours.
Correct: E) Fitz-Hugh-Curtis syndrome (perihepatitis from gonorrhea/chlamydia)
Concept: Fitz-Hugh-Curtis syndrome — RUQ pain, pelvic source Interpretation
Why E: Fitz-Hugh-Curtis = perihepatitis from gonorrhea/chlamydia ascending to the liver capsule — RUQ pain whose SOURCE is pelvic.
Discriminator: 'Patient has RUQ pain but the source is pelvic. Always ask about STI risk.'
| A) Acute cholecystitis | A normal gallbladder on ultrasound argues against gallstones — the pelvic findings are the story. |
| B) Viral hepatitis | No jaundice or transaminase pattern is given; cervical motion tenderness points pelvic. |
| C) Renal colic | Flank/colicky pain with hematuria — not the pattern here. |
| D) Splenic pathology | Perihepatitis involves the hepatic capsule, not the spleen. |
Trap: The gallbladder is normal on ultrasound — the RUQ pain still exists, so think liver capsule, not gallbladder.
Future alert: Treat as PID (ceftriaxone + doxycycline + metronidazole); retest STIs in 3 months.
Correct: A) Topical azole (clotrimazole or miconazole) × 7 days
Concept: Candidiasis in pregnancy — topical azoles only, no fluconazole Interpretation
Why A: Candidiasis in pregnancy: topical azoles only — no oral fluconazole (teratogenic).
Discriminator: pH <4.5 (normal) with pseudohyphae is classic candidiasis; the pregnancy twist makes topical therapy mandatory.
| B) Fluconazole 150 mg PO single dose | Teratogenic — DO NOT use in pregnancy; topical azoles are the pregnancy regimen. |
| C) Metronidazole 500 mg PO BD × 7 days | Metronidazole treats BV and trichomoniasis, not candidiasis. |
| D) Clindamycin 2% vaginal cream | A BV regimen, not candidiasis. |
| E) Tinidazole 2 g PO single dose | Trichomoniasis treatment — wrong pathogen and wrong indication. |
Trap: Fluconazole is the reflex 'uncomplicated candidiasis' answer — pregnancy flips it to topical azoles.
Future alert: If recurrent (≥4/year): induction then maintenance fluconazole — but only after pregnancy.
Correct: B) Metronidazole 2 g PO single dose AND treat her partner
Concept: Trichomoniasis — treat the partner (STI) Interpretation
Why B: Trichomoniasis: metronidazole 2 g PO single dose (safe in all trimesters) + treat the partner — an STI, unlike BV and candidiasis.
Discriminator: BV and candidiasis: NO partner treatment. Trichomoniasis: YES — 'a classic exam discriminator.'
| A) Metronidazole for her only; partner not treated | Trichomoniasis is an STI — the partner MUST be treated even if asymptomatic. |
| C) Topical clotrimazole cream × 7 days | Antifungal — wrong pathogen (this is a protozoan). |
| D) Clindamycin 2% vaginal cream | A BV option; it neither covers trichomonads nor treats the partner. |
| E) Treat partner only if symptomatic | An asymptomatic untreated partner guarantees reinfection. |
Trap: The partner-treatment point is the trap: BV/candida ≠ trich.
Future alert: Test for other STIs; retest in 3 months.
Correct: C) Myomectomy (hysteroscopic, laparoscopic, or open)
Concept: Fibroids + fertility → myomectomy Analysis
Why C: Fertility desired → myomectomy. 'This is a classic exam point — young woman wants children, what surgery?'
Discriminator: Submucosal fibroids cause the most bleeding and infertility; hysteroscopic myomectomy suits those, open myomectomy for large or multiple fibroids.
| A) Hysterectomy | Definitive for bleeding but destroys fertility — wrong for a woman who wants children. |
| B) Uterine artery embolization (UAE) | Effective for symptoms but NOT recommended when future fertility is desired. |
| D) Endometrial ablation | Prevents pregnancy — for HMB without fertility desire. |
| E) Watchful waiting with GnRH agonists alone | GnRH shrinks fibroids 30-50% but is temporary (add-back needed past 3 months); surgical planning still needs myomectomy. |
Trap: Hysterectomy is the definitive fibroid treatment — but the fertility clause flips the answer to myomectomy.
Future alert: Conceive 3-6 months after surgery; monitor for recurrence.
Correct: D) Submucosal (protrudes into the uterine cavity)
Concept: Fibroid location — most bleeding = submucosal Recall
Why D: Submucosal fibroids protrude into the endometrial cavity → the MOST bleeding and the MOST fertility problems.
Discriminator: Best imaging for submucosal fibroids: hysteroscopy or saline infusion sonography.
| A) Subserosal (projects outward) | Causes pressure symptoms and torsion risk — minimal bleeding. |
| B) Intramural (within the myometrium) | The most common type with bulk symptoms — not the biggest bleeder. |
| C) Pedunculated subserosal | Carries torsion risk; bleeding is not its hallmark. |
| E) Calcified/atrophic fibroid | Postmenopausal involution; not a heavy bleeder. |
Trap: 'Intramural = most common' is the distractor — the question asks about bleeding.
Future alert: Hysteroscopic myomectomy for submucosal lesions; map with SIS/hysteroscopy.
Correct: E) Laparoscopy with biopsy
Concept: Endometriosis — gold standard: laparoscopy with biopsy Interpretation
Why E: Laparoscopy with biopsy = gold standard — direct visualization (powder-burn/black-blue lesions) plus histology.
Discriminator: The 3 Ds (dysmenorrhea, dyspareunia, dyschezia) + infertility point strongly; laparoscopy confirms and can treat in the same sitting.
| A) Transvaginal ultrasound showing a ground-glass cyst | TVS detects endometriomas (ground glass) but cannot detect peritoneal disease — and is not the gold standard. |
| B) Elevated CA-125 | Not diagnostic — also elevated in fibroids, PID, and pregnancy. |
| C) MRI pelvis | Useful adjunct, not the gold-standard tissue diagnosis. |
| D) Response to a GnRH agonist trial | Empiric treatment does not confirm the diagnosis. |
Trap: Ground-glass endometrioma on US is diagnostic FOR an endometrioma — but the gold standard for endometriosis remains laparoscopy + biopsy.
Future alert: Laparoscopic excision (pain relief 60-80%); natural conception for 6-12 months; IVF if unsuccessful.
Correct: A) Six months of GnRH agonist suppression
Concept: Endometriosis + fertility — medical suppression is counterproductive Analysis
Why A: Medical suppression suppresses ovulation → counterproductive for fertility. 'Medical helps pain, not fertility.'
Discriminator: The source is blunt: medical treatment only SUPPRESSES endometriosis; it does not cure it. For fertility: surgery, then conception or IVF.
| B) Laparoscopic excision of lesions | Restores anatomy and is the fertility-oriented surgical approach. |
| C) Attempt natural conception for 6-12 months after surgery | The standard post-excision fertility plan. |
| D) IVF | Appropriate if natural conception fails or other factors exist. |
| E) NSAIDs for pain during menses | Analgesia is compatible with fertility attempts. |
Trap: Pain relief and fertility are different goals in endometriosis — suppression wins for pain but loses for conception.
Future alert: Post-excision: timed natural conception; refer for IVF at 6-12 months if unsuccessful.
Correct: B) Proceed to surgery (detorsion) despite normal Doppler
Concept: Ovarian torsion — Doppler does NOT rule it out Analysis
Why B: Sudden severe unilateral pelvic pain + mass + vomiting = torsion until proven otherwise; Doppler flow does NOT rule it out (intermittent torsion). Highest risk: 5-10 cm masses.
Discriminator: Do not delay surgery for imaging; detorse and consider oophoropexy to prevent recurrence.
| A) Reassure — normal Doppler excludes torsion | Torsion can be intermittent; normal Doppler flow does NOT exclude it. |
| C) Repeat ultrasound in 6 hours | Torsion is a surgical emergency — do not delay surgery for imaging. |
| D) Analgesia, discharge, pelvic MRI in a week | Clinical diagnosis gates surgery; delay risks ovarian necrosis. |
| E) Immediate oophorectomy without detorsion attempt | Detorsion first — preserve the ovary even if dusky; oophorectomy only if clearly non-viable after detorsion. |
Trap: The Doppler result is a deliberate trap — 'if clinical suspicion is high, proceed to surgery regardless of Doppler.'
Future alert: Laparoscopy: detorsion + cystectomy; oophoropexy if recurrence risk.
Correct: C) Meigs syndrome (ovarian fibroma + ascites + pleural effusion)
Concept: Meigs syndrome — fibroma + ascites + pleural effusion (benign) Recall
Why C: Ovarian FIBROMA + ascites + pleural effusion = Meigs syndrome — BENIGN, resolving after tumor removal; do not confuse with malignant ascites.
Discriminator: Fibroma is the benign solid tumor in the Meigs triad; the source flags it explicitly to avoid overcalling malignancy.
| A) Epithelial ovarian cancer with malignant ascites | Malignant ascites would not resolve from resection of a benign fibroma; a normal CA-125 fits Meigs. |
| B) Tubo-ovarian abscess | Infection — fever and adnexal mass; no ascites-pleural effusion complex. |
| D) Endometrioma (chocolate cyst) | Old blood inside the ovary — no ascites-pleural effusion syndrome. |
| E) Mature cystic teratoma (dermoid) | Hair/teeth/sebum tumor — not the Meigs triad. |
Trap: Ascites + effusion + pelvic mass screams 'ovarian cancer' — the mass is a benign fibroma.
Future alert: Cystectomy/oophorectomy; effusion and ascites resolve postoperatively.
Correct: D) Vaginal childbirth
Concept: POP — most common cause is vaginal childbirth Recall
Why D: Most common cause of POP = vaginal childbirth (fascial and levator injury). Symptoms worsen at end of day (gravity) and improve lying down.
Discriminator: POP-Q grading; first-line for stage I-II is conservative — Kegels and pessary.
| A) Chronic constipation | A contributor and heavy-lifting risk, but childbirth is the dominant cause. |
| B) Postmenopausal estrogen loss alone | Atrophy worsens prolapse but does not cause the fascial damage of childbirth. |
| C) Prior hysterectomy | Contributes to vault prolapse, not the most common overall cause. |
| E) Chronic cough | Raises intra-abdominal pressure — a risk factor, not the primary cause. |
Trap: Perimenopausal and postpartum risk factors are the distractors; childbirth is the 'most common cause' pearl.
Future alert: Stage I-II → pelvic floor training + pessary; stage III-IV or failed conservative → native-tissue repair or sacrocolpopexy.
Correct: E) Sacrocolpopexy (suspend the vaginal vault to the sacrum)
Concept: Vault prolapse — sacrocolpopexy is gold standard Recall
Why E: Sacrocolpopexy = gold standard for vault prolapse repair — suspending the vagina to the sacral promontory, with the lowest recurrence rate.
Discriminator: Colpocleisis is the alternative for poor surgical candidates who are not sexually active (high success, low morbidity).
| A) Anterior colporrhaphy | Repairs cystocele (anterior wall), not apical/vault prolapse. |
| B) Posterior colporrhaphy | Repairs rectocele, not the vault. |
| C) Colpocleisis | Obliterative option for elderly non-sexually-active patients — not the gold-standard repair. |
| D) Vaginal hysterectomy | There is no uterus to remove — hysterectomy cannot fix vault prolapse. |
Trap: 'Vaginal hysterectomy' is the trap — the uterus is already gone; the apex needs suspension.
Future alert: Laparoscopic/robotic sacrocolpopexy with mesh; pessary if non-surgical.
Correct: A) Pelvic floor exercises (Kegels) for a minimum of 8 weeks
Concept: Stress incontinence — Kegels are first-line Interpretation
Why A: Stress incontinence (leaks with ↑ intra-abdominal pressure, no urgency, normal PVR) → first-line: Kegels for a minimum of 8 weeks, 50-70% improvement.
Discriminator: Surgery (mid-urethral sling) is the escalation step, not the first line — the source is explicit about the ordering.
| B) Mid-urethral sling (TVT/TOT) | The most common SURGICAL treatment (80-90% cure) — but conservative therapy comes first. |
| C) Anticholinergics (oxybutynin) | For urge incontinence/detrusor overactivity — this is stress incontinence. |
| D) Botox detrusor injection | For refractory OAB — not stress incontinence. |
| E) Mirabegron | A β3 agonist for OAB, not stress leakage. |
Trap: The sling is the seductive 'definitive' answer — the question asks first-line, and that is Kegels.
Future alert: If improvement is insufficient after 8-12 weeks: mid-urethral sling or Burch colposuspension.
Correct: B) Post-void residual >200 mL
Concept: Overflow incontinence — PVR >200 mL Interpretation
Why B: Overflow: bladder overdistension → constant dribbling, weak stream, incomplete emptying; the key diagnostic is PVR >200 mL.
Discriminator: Treatment targets the underlying cause — surgery for obstruction or clean intermittent self-catheterization for detrusor underactivity.
| A) Post-void residual of 40 mL | Normal PVR (<50-100 mL) — fits stress or urge, not overflow. |
| C) Leakage only with laughter | Stress pattern — pressure-triggered leakage. |
| D) Sudden strong urge with nocturia | Urge incontinence/OAB pattern. |
| E) Normal pelvic floor tone | Irrelevant to obstruction or detrusor underactivity causing overflow. |
Trap: The dribbling + weak stream + incomplete-emptying triad points to retention physiology; PVR is the confirmatory number.
Future alert: Urodynamics; treat obstruction; self-catheterization if detrusor underactivity.
Correct: C) Postcoital bleeding
Concept: Cervical cancer — most common symptom is postcoital bleeding Recall
Why C: Postcoital bleeding is the most common presenting symptom of cervical cancer — examine the cervix and do a Pap; do not dismiss it as benign.
Discriminator: 70% are squamous cell carcinoma arising at the transformation zone; HPV 16/18 cause ~70% of cases; progression from HPV to invasive cancer takes 10-20 years.
| A) Postmenopausal bleeding | The classic symptom of ENDOMETRIAL cancer — a different malignancy. |
| B) Purulent vaginal discharge | Suggests cervicitis — not the leading symptom of cervical cancer. |
| D) Deep pelvic pain radiating to the back | A late-stage symptom, not the most common presentation. |
| E) Urinary frequency | A bulk/pressure symptom — not the classic red flag. |
Trap: PMB is the 'most common symptom' for ENDOMETRIAL cancer — the two gyn cancers are designed to be swapped.
Future alert: Speculum exam, Pap/HPV, colposcopy with biopsy of the visible lesion.
Correct: D) Immediate referral for colposcopy with biopsy
Concept: HSIL on Pap → immediate colposcopy with biopsy Interpretation
Why D: HSIL on Pap = prompt colposcopy with biopsy. CIN 2-3 requires treatment (LEEP/cone); CIN 1 may regress and is observed.
Discriminator: Screening catches the 10-20-year slow progression; HSIL is the referral trigger, not a repeat-Pap trigger.
| A) Repeat Pap in 1 year | HSIL requires immediate colposcopy — 'do not repeat Pap.' |
| B) Co-testing (Pap + HPV) in 5 years | That is the routine screening interval, not the response to an HSIL result. |
| C) Administer the HPV vaccine | Vaccination is primary prevention, not management of established HSIL. |
| E) LEEP directly without colposcopy | Treatment is guided by colposcopic biopsy; LEEP follows confirmed CIN 2-3. |
Trap: The guideline says 'don't repeat Pap' — colposcopy is the immediate destination.
Future alert: Biopsy → CIN 2-3: LEEP/cone; then continue screening for 25 years (never stop at 65 after treatment).
Correct: E) Co-testing (Pap + HPV) every 5 years OR Pap alone every 3 years
Concept: Screening intervals — 30-65: co-testing every 5 years Recall
Why E: Age 30-65: co-test (Pap + HPV) every 5 years OR Pap alone every 3 years. Start at 21; stop at 65 with adequate prior screening.
Discriminator: After CIN 2+ treatment, continue screening for 25 years — never stop at 65 for treated patients.
| A) Annual co-testing | Annual screening is not recommended by any modern guideline for average-risk women. |
| B) Pap alone every 5 years | At age 30-65 the co-test runs every 5 years; Pap-alone every 5 years is not a guideline option. |
| C) Stop screening — adequate prior negatives | Ceasing screening applies at age 65 with adequate prior screening, not at 32. |
| D) HPV vaccination instead of screening | Vaccination does not eliminate screening — the vaccine covers 9 of many cancer-causing types. |
Trap: The interval list is a memory trap — at 30-65 the co-test option runs every 5 years.
Future alert: If co-test is negative → next in 5 years; if HPV-positive with abnormal cytology → colposcopy.
Correct: A) Endometrial biopsy (Pipelle)
Concept: Endometrial cancer — stripe ≥5 mm → biopsy Interpretation
Why A: PMB (any bleeding after 12 months of amenorrhea) = endometrial cancer until proven otherwise; stripe ≥5 mm → biopsy regardless of appearance.
Discriminator: Stripe <5 mm = <1% cancer risk (observe); ≥5 mm = biopsy. Obesity (BMI 36) is the dominant unopposed-estrogen risk factor.
| B) Observe with repeat TVS in 3 months | Any PMB with a stripe ≥5 mm requires biopsy — observation is unsafe. |
| C) Start progestin and reassess symptoms | Empiric hormones without a tissue diagnosis are inappropriate for PMB. |
| D) MRI pelvis for staging | Staging follows a tissue diagnosis, it does not precede it. |
| E) Saline infusion sonography | Useful for focal lesions and cavity anatomy — not the first diagnostic step here. |
Trap: 8 mm is clearly above threshold — the trap would be a borderline 5-6 mm stripe tempting watchful waiting.
Future alert: Pipelle (90% sensitive); if inadequate → hysteroscopy with D&C.
Correct: B) Combined oral contraceptive use
Concept: Endometrial cancer prevention — OCPs protect the endometrium Recall
Why B: Combined OCPs DECREASE endometrial cancer risk — progesterone protects the endometrium. 'Never tell a patient OCPs cause endometrial cancer.'
Discriminator: The same OCPs also reduce ovarian cancer risk (~50%, via the incessant-ovulation hypothesis).
| A) Tamoxifen therapy | Tamoxifen is a partial estrogen agonist in the endometrium — it INCREASES endometrial cancer risk. |
| C) Unopposed estrogen replacement | The classic risk factor — it drives hyperplasia to carcinoma. |
| D) Late menopause | Longer unopposed estrogen exposure increases the risk. |
| E) Obesity | Adipose aromatase converts androgens to estrogen — the most important modifiable risk factor. |
Trap: Three distractors are risk factors — especially obesity; the question asks what protects.
Future alert: Counsel contraception choice and endometrial protection for obese perimenopausal women.
Correct: C) Residual disease after optimal debulking (no visible residual)
Concept: Ovarian cancer — most important prognostic factor: optimal debulking Recall
Why C: The single most important prognostic factor in ovarian cancer = the amount of residual disease after debulking. Optimal = no visible residual.
Discriminator: 75% present at stage III-IV; chemotherapy is carboplatin + paclitaxel × 6 cycles; PARP inhibitors for BRCA-mutated disease.
| A) Preoperative CA-125 level | CA-125 is for monitoring — explicitly not for screening or prognosis. |
| B) Tumor laterality | Unilateral vs bilateral disease does not govern prognosis like residual disease does. |
| D) Age at diagnosis | Age matters broadly, but residual disease is THE prognostic factor the source emphasizes. |
| E) Histologic grade alone | Grade informs biology; residual disease after surgery remains dominant. |
Trap: CA-125 is the tempting biomarker answer — it is explicitly 'for monitoring, NOT for screening/prognosis'.
Future alert: Adjuvant carboplatin + paclitaxel; maintenance PARP if BRCA-mutated; surveillance with exam + CA-125 every 2-4 months.
Correct: D) Risk-reducing salpingo-oophorectomy (RRSO) at age 35-40
Concept: BRCA1 carrier — RRSO is the prevention Interpretation
Why D: RRSO at age 35-40 for BRCA carriers reduces ovarian cancer risk by 80-90%; BRCA1 lifetime ovarian risk is 40-50%.
Discriminator: The source is explicit: CA-125 + TVS screening is 'NOT recommended' — surgery is the prevention.
| A) Annual CA-125 + transvaginal ultrasound screening | Screening with CA-125 + TVS is NOT recommended — no mortality benefit, poor sensitivity and specificity. |
| B) Combined OCPs alone | OCPs reduce ovarian cancer risk ~50%, but RRSO is the definitive risk-reducing surgery for BRCA carriers. |
| C) Tamoxifen chemoprevention | Tamoxifen is breast-cancer chemoprevention, not ovarian. |
| E) Annual pelvic MRI | No evidence for MRI screening of ovarian cancer in BRCA carriers. |
Trap: The screening option is designed to feel responsible — the guideline explicitly rejects it.
Future alert: Genetic counseling first; RRSO; discuss HRT until natural-menopause age for symptoms (with oncology input).
Correct: E) LARC — LNG-IUS, copper IUD, or implant
Concept: LARC = most effective reversible contraception Recall
Why E: LARC (IUD + implant) = the most effective reversible contraception (>99% typical use) — superior to OCPs, patch, and ring.
Discriminator: The most effective EMERGENCY contraception is also the copper IUD (>99%, insert within 5 days).
| A) Combined oral contraceptive pill | >99% perfect use but 91% typical use — LARC exceeds it with set-and-forget compliance. |
| B) DMPA (Depo-Provera) | >99% perfect / 94% typical — plus the bone-density caution beyond 2 years. |
| C) Male condoms | The only method with STI protection, but typical-use failure around 13%. |
| D) Vaginal ring | Still user-dependent — below the >99%/>99% of IUDs and the implant. |
Trap: The COC is the default 'effective' answer — the exam asks for the MOST effective reversible.
Future alert: Offer an IUD (copper or LNG-IUS) or implant; add condoms for STI protection.
Correct: A) Copper IUD insertion (>99%, within 5 days)
Concept: Emergency contraception — copper IUD is most effective Interpretation
Why A: Copper IUD = the most effective emergency contraception (>99%, insert within 5 days); it also provides ongoing contraception.
Discriminator: Levonorgestrel works up to 3 days; ulipristal to 5 days (better with high BMI). The IUD wins on efficacy and adds long-term coverage.
| B) Levonorgestrel EC pill (Plan B) | Effective up to 3 days, most effective under 24 hours — but inferior to the copper IUD. |
| C) Ulipristal acetate | Effective to 5 days and better than levonorgestrel with a high BMI — still not the >99% copper IUD. |
| D) Combined OCPs (Yuzpe method) | Less effective and more side effects — not the top option. |
| E) Regular combined OCP continuation | Not an emergency contraception method at all. |
Trap: Pills are the reflexive 'EC' answer — the IUD is the efficacy champion.
Future alert: Insert the IUD, screen for STIs, counsel ongoing method use.
Correct: B) To protect the endometrium from unopposed estrogen → hyperplasia/cancer
Concept: HRT — progestin required when the uterus is present Analysis
Why B: Unopposed estrogen in a woman with a uterus causes endometrial hyperplasia → cancer. Always add progestin when the uterus is present.
Discriminator: Post-hysterectomy: estrogen-only is fine — no endometrium to protect. Vaginal estrogen stays very low absorption for genitourinary symptoms.
| A) To reduce the risk of venous thromboembolism | Progestin does not reduce VTE — estrogen dose/route and patient factors do. |
| C) To improve bone mineral density | Estrogen alone does that; progestin's role is endometrial protection. |
| D) To prevent breast cancer | Combined HRT carries a small INCREASED breast cancer risk (WHI) — it is not prevention. |
| E) To enhance the vasomotor effect | Progestin is added for safety, not efficacy. |
Trap: The WHI data make 'breast cancer' a tempting distractor — but the progestin rationale here is endometrial.
Future alert: Continuous combined regimen; annual review of symptoms, bleeding, and risk factors.
Correct: C) SSRI/SNRI (paroxetine, venlafaxine) or gabapentin
Concept: HRT contraindicated after breast cancer — non-hormonal options Analysis
Why C: Breast cancer = absolute HRT contraindication. Non-hormonal options: SSRIs/SNRIs (paroxetine, venlafaxine) reduce hot flashes 40-50%; gabapentin is similar.
Discriminator: Vaginal estrogen (very low systemic absorption) may be discussed with oncology for genitourinary symptoms — but systemic HRT is off the table.
| A) Estrogen-only HRT | Breast cancer (current or history) is an ABSOLUTE contraindication to systemic HRT. |
| B) Estrogen + progestin HRT | Also absolutely contraindicated after breast cancer. |
| D) Tibolone | A hormonal agent — same contraindication logic. |
| E) Clonidine as the first choice | Clonidine is less effective (dry mouth, drowsiness, hypotension) — SSRIs/SNRIs and gabapentin are preferred. |
Trap: The vignette plants breast cancer specifically to forbid systemic HRT — pick the non-hormonal class.
Future alert: Paroxetine/venlafaxine or gabapentin; lifestyle measures (layering, avoiding triggers).
Correct: D) Ultrasound
Concept: Breast mass <30 years — first imaging is ultrasound Recall
Why D: Women <30 with a breast mass → ultrasound first (dense breast tissue); mammogram is first-line after 40.
Discriminator: Fibroadenoma is the most common benign breast tumor ('breast mouse'); mammogram only if >30 years.
| A) Mammogram | First-line after 40 years — dense young breast tissue limits mammographic sensitivity. |
| B) MRI breast | Reserved for high-risk screening or lesion characterization, not first-line young-woman imaging. |
| C) CT chest with contrast | Ionizing radiation; not a breast mass workup modality. |
| E) Sestamibi scintimammography | Not a standard first-line investigation. |
Trap: Mammogram is the reflex 'breast imaging' answer — the age clause (<30) flips it to ultrasound.
Future alert: Well-defined hypoechoic oval mass → fibroadenoma; excise if >2 cm, growing, or patient preference.
Correct: E) Continue breastfeeding AND start dicloxacillin/cephalexin × 10-14 days
Concept: Mastitis — continue breastfeeding Interpretation
Why E: Mastitis: S. aureus (MRSA if severe); dicloxacillin/cephalexin 500 mg QID × 10-14 days; DO NOT stop breastfeeding.
Discriminator: Abscess (fluctuant mass) → needle aspiration or I&D plus continued antibiotics.
| A) Stop breastfeeding and pump-and-discard | Continuing breastfeeding drains the infected milk and is safe for the baby — do not stop. |
| B) Start fluconazole orally | Fluconazole treats candida/nipple thrush — this is bacterial mastitis (S. aureus). |
| C) Antibiotics only if an abscess is drained | Mastitis without abscess is treated with antibiotics promptly; do not wait for fluctuance. |
| D) Ice packs and NSAIDs alone | Antibiotics are required for bacterial mastitis with fever. |
Trap: 'Stop breastfeeding' is counterintuitive but exactly wrong — continuation is therapeutic.
Future alert: If fluctuance develops → ultrasound-guided aspiration/I&D; complete the antibiotic course.
Correct: A) Start mammography at age 40-50 (USPSTF: 50 biennial; ACS: 45 annual or 40 optional)
Concept: Average-risk breast screening — start at 40-50 Recall
Why A: Average risk: USPSTF biennial from 50; ACS annual from 45 (option at 40). Stop only if life expectancy is <10 years.
Discriminator: BSE is NOT recommended for screening (no mortality benefit); breast awareness is encouraged.
| B) Start at age 30 with annual MRI | That is HIGH-risk screening (BRCA, strong family history, chest radiation) — not average risk. |
| C) Screening is already overdue at 35 | No guideline starts average-risk screening at 35. |
| D) Stop at 50 — no further screening | Screening continues through the 50s-70s; stopping at 50 is wrong. |
| E) No screening needed without symptoms | Screening exists precisely for asymptomatic women. |
Trap: The source warns intervals vary (USPSTF biennial vs ACS annual) — know both; the anchor is 40-50 start.
Future alert: Biennial or annual mammography; reassess risk (BRCA testing if strong family history).
Correct: B) Annual mammogram + MRI starting at age 30
Concept: High-risk (BRCA) screening — mammogram + MRI from age 30 Interpretation
Why B: High-risk (BRCA, strong family history, chest radiation age 10-30): annual mammogram + MRI from age 30 (or 8 years before the earliest family diagnosis).
Discriminator: MRI is more sensitive in dense breasts; chemoprevention (tamoxifen), prophylactic mastectomy, and RRSO are risk-reduction options.
| A) Biennial mammogram starting at 50 | That is the average-risk USPSTF regimen — BRCA carriers need intensified screening. |
| C) MRI alone without mammogram | MRI alone is not the regimen; MRI complements mammography annually. |
| D) Breast self-exam monthly only | BSE is not recommended for screening in ANY risk group. |
| E) Mammogram every 3 years from 40 | Insufficient for a carrier with a 40-50% lifetime risk. |
Trap: The average-risk answer is the trap — genetics change both the modality and the start age.
Future alert: Annual MRI + mammogram; genetic counseling; discuss risk-reducing surgery timing.
Correct: C) Vaginal estrogen (cream, tablet, or ring)
Concept: GSM — menopausal dyspareunia → vaginal estrogen Interpretation
Why C: Postmenopausal superficial dyspareunia + dryness = vulvovaginal atrophy (GSM) → vaginal estrogen (very low systemic absorption; no progestin needed).
Discriminator: Location tells origin: superficial (entry) = atrophy, vulvodynia, infection, vaginismus; deep = endometriosis, PID, ovarian cysts.
| A) Systemic combined HRT | Systemic HRT treats vasomotor symptoms; GSM responds better to local estrogen with minimal absorption. |
| B) Flibanserin | Indicated for HSDD (low desire), not entry dyspareunia. |
| D) Vaginal dilators alone | Dilators are for vaginismus; the primary driver here is estrogen-deficient atrophy. |
| E) Ospemifene as first-line | Ospemifene (an oral SERM) is an option if estrogen cannot be used — vaginal estrogen is the standard first-line. |
Trap: 'Systemic HRT' tempts — local estrogen is the targeted, low-risk first-line for GSM.
Future alert: Vaginal estrogen; lubricants for intercourse; if estrogen is not acceptable, ospemifene or moisturizers.
Correct: D) Low sexual desire (hypoactive sexual desire disorder)
Concept: Most common female sexual complaint — low desire (HSDD) Recall
Why D: The most common female sexual complaint = low desire (HSDD). Use the PLISSIT model for the sexual history.
Discriminator: HSDD treatment: address underlying causes, optimize medications, consider flibanserin (Addyi) or off-label testosterone.
| A) Orgasmic disorder | Common but not the most common complaint. |
| B) Vaginismus | A specific entry-pain condition — much less frequent. |
| C) Deep dyspareunia | A symptom with pelvic causes — not the leading complaint. |
| E) Genital arousal disorder | Less common than desire complaints. |
Trap: Pain disorders are vivid — but prevalence belongs to desire.
Future alert: Screen for depression/anxiety/relationship factors; consider flibanserin or topical testosterone after etiology review.
Correct: E) Androgen-secreting ovarian or adrenal tumor
Concept: Rapid virilization → androgen-secreting tumor Interpretation
Why E: Rapid onset of virilization + very high testosterone = androgen-secreting tumor (NOT PCOS) — image the adrenals and ovaries.
Discriminator: The source's red-flag list pairs 'rapid virilization + very high testosterone' explicitly against PCOS.
| A) Polycystic ovary syndrome | Virilization in PCOS is gradual, mild, and accompanied by oligomenorrhea since adolescence — NOT rapid onset. |
| B) Late-onset congenital adrenal hyperplasia | A chronic disorder; rapid virilization with very high testosterone points to tumor, not CAH. |
| C) Cushing syndrome | Features such as striae, proximal weakness, and hypercortisolism do not match rapid virilization with extreme testosterone. |
| D) Prolactinoma | Causes galactorrhea and amenorrhea, not virilization. |
Trap: PCOS is the camouflage — the velocity of onset and the testosterone level unmask the tumor.
Future alert: Adrenal/ovarian imaging, testosterone and DHEAS levels, surgical resection.
Correct: A) Leiomyosarcoma
Concept: Rapid fibroid growth postmenopause → leiomyosarcoma Recall
Why A: Fibroids should shrink after menopause — RAPID growth in a postmenopausal woman = suspect leiomyosarcoma (rare but aggressive).
Discriminator: This is one of the chapter-23 red flags: 'Rapidly growing fibroid in postmenopausal woman → Suspect leiomyosarcoma.'
| B) Red degeneration | A pregnancy-related hemorrhagic infarction — not postmenopausal rapid growth. |
| C) Normal estrogen-driven growth | Fibroids SHRINK after menopause (estrogen-dependent) — growth is abnormal. |
| D) Ovarian torsion | Acute pain with a mass — but the story is rapid uterine growth, not cystic ovarian torsion. |
| E) Endometriosis progression | Endometriosis does not present as rapid postmenopausal uterine growth. |
Trap: The pregnancy red-degeneration pearl is a sly distractor — the menopausal context changes the answer entirely.
Future alert: Imaging plus surgical evaluation (hysterectomy with morcellation precautions); oncology referral.
This MedCORE is not a medical textbook. It is only designed for rapid, last-minute recall and should be treated like a high-yield cheat sheet, not a complete learning resource. Use it to memorize critical algorithms and recognition patterns.